Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Level Three: Here’s where an agent or broker comes in. Agents work on behalf of companies and deal primarily with wholesalers. From here, the wholesalers sell to retailers who then sell to consumers.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156025337
Stock price goes up and down however PCTL is not playing around
The company is growing by leaps and bounds
When the fundamentals catch up you will want to be around
From the Stock Podcast dated May 8, 2020:
Additional hospital installations of PCT Corp.’s Annihilyzer® Infection Control Systems are expected to continue throughout the end of the month and into the summer.
“Our fluid sales and distribution activities have helped facilitate growth and business expansion,” explains CEO Gary Grieco. “With our hospital installations now on track as well, we’re full steam ahead on multiple fronts. It’s a very serious, but exciting time for us.
From the Stock Podcast dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
Grieco then addressed rumors that the Company is expanding into China. Grieco shared that the Company signed an MOU in January of 2020, which required the Company to deliver systems. “When the pandemic broke, we took that out of the equation,” said Grieco. “What we have done is tabled any discussions until late summer,” he continued. “I don’t feel that we should be shipping any systems anywhere as long as we need them here in the United States.”
If they are going to start with five systems to the UK who are the other 20 systems for?
There is information we just don't know about yet.
It is my belief that during the run on HOCI, PCTL got some orders for Annihilyzers and I believe those machines are going somewhere in America.
From the Press Release dated April 16, 2020:
The company continues to expand domestically as well. Following an earlier release dated April 14th , the company is also announcing an additional purchase order for PCT Corp.’s Annihilyzer® Infection Control Systems in New York City.
“With three PO’s for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases,” says Grieco. “We are on pace for unprecedented and record growth in all areas of our business.”
From the Press Release dated April 14, 2020:
The company believes that once the current travel restrictions are lifted, they will be able to continue their plans for accelerated placements of Annihilyzer® systems in New York City and elsewhere. “We have a number of interested parties in our sales pipeline,” adds Grieco.
From the Press Release dated April 7, 2020:
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.
Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States.
From the Press Release dated March 25, 2020:
PCTL is continuing to expand business operations at a rapid rate while experiencing a dramatic increase in inquiries and orders from new and existing clients.
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
Jody Read, COO stated: “We are still continuing to see significant interest in the facility-based Annihilyzer® Infection Control System. However, we are not able to coordinate installations due to travel restrictions and availability of hospital staff to implement the systems. We are continuing to build systems and at the same time utilize our current South Carolina facility’s capabilities with large volume systems to produce mass quantities of disinfectant for distributors and hospitals.
The Annihilyzer® Infection Control System remains the company’s flagship product and continues to garner intense interest from prospective hospitals and healthcare facilities.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
Also while all this was going on there was an unprecedented demand for Infection Control Systems worldwide that couldn't be met.
https://www.forbes.com/sites/richblake1/2020/04/17/in-covid-19-fight-robots-report-for-disinfection-duty/#14cbcc722ada
Large-scale coronavirus testing continues to lag and a vaccine could be at least one year away. But in the battle against world pandemic a rapidly expanding brigade of robots is answering an urgent call of duty: surface disinfection.
They're rolling in by the hundreds and not just into hospitals and nursing homes but across a wide spectrum of public spaces, including government buildings, offices, hotels, airports and universities. Administrators of all stripes, desperate to keep people safe, are looking to a global robotics industry that has been quick to respond.
"Hospitals around the world are waking up to autonomous disinfection," Nielsen said. "We can't build these robots fast enough.
"Healthcare-sector suppliers like UVD, Xenex and others still are a long way from being able to meet exploding global demand for automated disinfection solutions but it's not just specialized service robots riding into battle.
Let us connect some dots:
1. Hypochlorous Acid sales through the roof.
2. Demand for Infection Controls Systems exploding.
If you are in need of Hypochlorous Acid and an Infection Controls Systems where do you go.
There are many companies that sell Infection Controls Systems.
There are many companies that sell Hypochlorous Acid.
There are very few companies besides PCTL that can give both in one system.
I would be shocked if PCTL didn't get many orders for their system based on the demand for their products.
Two for the Price of one.
FACTS not fiction
Interesting.....Timely.....Accurate.....
Times have changed:
https://pureandclean.us/hypochlorous-acid/
Why isn’t Hypochlorous Acid everywhere?
The overwhelming impediment to its widespread use has been a lack of shelf stability. HOCl is the most reactive ROS (Reactive Oxygen Species). This means it reacts very easily and will quickly turn back into salt water. HOCl solutions have been used for over 100 years. in the early 1900's during the World Wars, HOCl solutions were used for disinfecting medical equipment and dressing wounds. However, until recently, HOCl solutions would only remain stable for about 90 minutes before turning back into salt water.
What has changed?
HOCl is now manufactured in a way that allows the solution to be stable for much longer than previously available. This has allowed for product to be carefully bottled and made available across the world. Although producing HOCl solutions is not challenging, stabilizing the solution is very difficult. In fact, at Pure&Clean our quality ingredients and unique process produce an unmatched product. This is proven by our HOCl industry-best 24-month (not impacted by opening) FDA cleared shelf life on all of our FDA cleared products. Furthermore, we do not add unnecessary ingredients to stabilize or preserve our product stability. The Pure&Clean solution is so stable that we are able to provide a very unique and rare HOCl Hydrogel product - which proves to have a massive impact across a number of medical applications.
2018 MDM Market Leaders | Top Jan-San Distributors
https://www.mdm.com/2018-top-jan-san-distributors
This list does not include master distributors.
1. SupplyWorks (The Home Depot, formerly Interline Brands)
2. Veritiv Corp. (facility solutions)
3. Bunzl
4. Staples (facilities and breakroom)
5. Imperial-Dade LLC
Amazon Business
W.W. Grainger (Jan-San)
Office Depot
Uline
Brady Industries
Waxie Sanitary Supply
Dalco
EBP Supply Solutions
Hill & Markes
HP Products - A Ferguson Enterprise
KelSan
Pollock Paper
Strauss Paper
The Fastenal Company (Jan-San)
WB Mason
Western Paper Distributors
From the PCTL Facebook page:
Yes, there’s plenty of Hydrolyte going out the door! Yes, we have a new “Level 3” Distributor to announce soon! Yes, we are working hard on our audit and financials! Yes, we care about our shareholders ??, the coronavirus ??, the SpaceX launch ??, our country’s future ??, and we care about changing the way the world controls dangerous, unwanted microorganisms ??. YES!
From the PR dated May 8, 2020:
“All of our potential distributors undergo a thorough vetting process,” says PCT Corp President Bill Prince. “We are looking to form strategic partnerships that will help us expand our existing presence; or establish a foothold in a new territory that we’ve identified.”
“The businesses we work with are looking to maintain their competitive edge as they establish declines to mention their distributors by name. “There’s a lot of competition out there in the disinfection space. Especially now,” adds Prince. “We have a tremendous amount of confidence in the businesses and people we work with.”
Finding a Distributor: 3 Things You Need to Know
Searching for a distributor can feel like a daunting task, but it’s not as overwhelming as most may fear. The best way to streamline the selection process is to do your homework, so you can have a clear understanding of exactly what you’re getting yourself into from the very beginning. Before you finalize your decision, there are a lot of variables to consider. To make sure you start this journey with your best foot forward, let’s discuss three major variables that could make or break the outcome of this venture.
Understand the Value of this Relationship
At first glimpse, this journey may seem like you’re meant to commit to endless meetings where you stand doe-eyed before a prized distributor pitching your product’s value to the company. When you really take a look at how this relationship is formed, you’ll begin to realize that benefits are shared across the board. In short, the distributor should be catering to you too!
It’s no secret that distributors can be really selective of the manufacturers they work with, but that’s for a good reason. Not only do these brands impact the distributor’s reputation – they benefit their bottom line as well.
You need to be as confident in your distributor as they are in you. While you’re searching for a provider that’s interested in expanding their horizons with the amazing product you’re laying out on the table, make sure you walk away from the situation feeling confident in the company’s ability to nurture your brand.
To find your business on the receiving end of the geographical expansion and skyrocketed sales that comes through joining forces with the right distributor is such a satisfying milestone in a budding company’s career. Just remember that you’re bringing plenty to the table as well.
I really don't have any idea to be honest, however I find it to be a big deal because the CEO mentioned it I believe for the first time.
That being said it may be PCTL allowing somebody else to focus on the HOCI sales which are basically on autopilot while our management focus on the flagship product, the Annihilyzer especially with the UK soon to come on board.
We will know more once we find who the level 3 distributor is.
Oh where oh where have my 10K gone I want it released so I can stop singing this song oh where oh where have my 10K gone
Don't you worry all you longs we be getting the 10K ready and it won't be long
Get all you can don't wait too long cause when the 2nd Q drop you'll be singing your own song
Liquid production March 15th -June 30th. ……. Sound correct?
max (3 shifts 7 days /wk)
106 shifts@ 14000gals/shift=1,484,000gal @ $8.00/gal=$11,872,000
Cost labor average 20.00/hrx 2544hrs=$50,880
min (1 shift 5days /wk)
78 shifts@14000gals/shift=1,092,000gal @ $8.00/gal=$8,736,000
Cost labor average 20.00/hr x 624 hrs=12,480
360x3=1080 shifts/yr x 14,000 gal/shift=15,120,000 x $8.00/gal= $120,960,000 / yr
Income on liquid only.
Are we wo Unit production 25/mo in S.C. 25/mo in Ft Wayne=50/mo starting July through Dec=300 units @ 8,000 / mo lease for 6 mos=$ 14,400,000
Est 14 units in NYC
2 units in UK
5 units some where= 21 units @ $8,000/unit=168,000/mo x 12mo=$2,016,000
$2,016,000+$14,400,000=$16,416,000
So how much does all this HOCI weigh?
plain water is 8.35 pounds per gallon, a 500 gallon totes net weight is 4,175 pounds. One ton is 2000 pounds, so a tote is over two tons. So if they've shipped just one... it's tons.
PCTL ships 5000 gallons per truck load.
What Is Product Distribution?
https://www.repsly.com/blog/consumer-goods/everything-you-need-to-know-about-product-distribution
Let’s get technical. Distribution entails making a product available for purchase by dispersing it through the market. It involves transportation, packaging, and delivery. Distribution is fundamental to a company’s sales.
A distributor is defined as someone who purchases products, stores them, and then sells them through a distribution channel. They are in between manufacturers and retailers or consumers, working on behalf of a particular company as opposed to representing themselves. Usually, distributors partake in collaborative relationships with clients and manufacturers.
The right distributor enhances a company’s exposure in the product market and can give an edge in terms of speed and efficiency.
Know Your Product Distribution Channels
A distribution channel refers to the flow of business that occurs between a manufacturer and a consumer. It is the path that a transaction follows. Distributors are the intermediaries that deliver and house products for producers to sell to retailers. These channels can be relatively simple or increasingly complex.
There are direct and indirect channels. In a direct channel, the producer works directly with the consumer. An indirect channel, on the other hand, incorporates intermediaries into the sales flow. There are four levels that break down the flow between manufacturers and consumers. When looking to expand into new markets or switch up your distribution strategy, you need to know the different levels of distribution.
Level Zero: A level zero distribution channel is the simplest. It involves a direct sale from manufacturers to consumers with no intermediary.
Level One: A level one channel has one intermediary as the middleman between the producer and consumer. An example is a retailer between manufacturer and consumer.
Level Two: When thinking about levels, associate the number to the number of intermediaries. In this case, a level two channel involves two intermediaries between producer and consumer. An example here would be a wholesaler selling to a retailer who then sells to the consumer.
Level Three: Here’s where an agent or broker comes in. Agents work on behalf of companies and deal primarily with wholesalers. From here, the wholesalers sell to retailers who then sell to consumers.
The Three Types of Distribution
Distribution strategies depend on the type of product being sold. the trick is knowing what type of distribution you will need to achieve your growth goals. There are three methods of distribution that outline how manufacturers choose how they want their goods to be dispersed in the market.
Intensive Distribution: As many outlets as possible. The goal of intensive distribution is to penetrate as much of the market as possible.
Selective Distribution: Select outlets in specific locations. This is often based on a particular good and its fit within a store. Doing this allows manufacturers to pick a price point that targets a specific market of consumer, therefore providing a more customized shopping experience. Selective distribution caps the number of locations in a particular area.
Exclusive Distribution: Limited outlets. This can mean anything from luxury brands that are exclusive to special collections available only in particular locations or stores. This method helps maintain a brand’s image and product exclusivity. Some examples of companies that enact exclusive distribution would be high-end designers like Chanel or even an automotive company lik
If you watch the video below the CEO says that they ship 5000 gallons per truckload.
https://www.myrtlebeachonline.com/news/local/article242025341.html
There was so much demand for it they rearranged their facility in Little River to make more of it. There are PRs with two 10,000 gallons orders with more in the pipeline.
From the PR dated March 25, 2020:
Following up on an earlier release from March 18th; a second 10,000-gallon fluid order has been shipped to an existing customer in the Midwest. Recurring orders to this sub-registrant are expected to follow in the coming weeks.
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
Just how much fluid have we sold, are selling or will sell moving forward is really not possible to predict however one of the other poster put together some very nice predictive analysis scenarios:
Liquid production March 15th -June 30th. ……. Sound correct?
max (3 shifts 7 days /wk)
106 shifts@ 14000gals/shift=1,484,000gal @ $8.00/gal=$11,872,000
Cost labor average 20.00/hrx 2544hrs=$50,880
min (1 shift 5days /wk)
78 shifts@14000gals/shift=1,092,000gal @ $8.00/gal=$8,736,000
Cost labor average 20.00/hr x 624 hrs=12,480
360x3=1080 shifts/yr x 14,000 gal/shift=15,120,000 x $8.00/gal= $120,960,000 / yr
Income on liquid only.
Are we wo Unit production 25/mo in S.C. 25/mo in Ft Wayne=50/mo starting July through Dec=300 units @ 8,000 / mo lease for 6 mos=$ 14,400,000
Est 14 units in NYC
2 units in UK
5 units some where= 21 units @ $8,000/unit=168,000/mo x 12mo=$2,016,000
$2,016,000+$14,400,000=$16,416,000
So how much does all this HOCI weigh?
plain water is 8.35 pounds per gallon, a 500 gallon totes net weight is 4,175 pounds. One ton is 2000 pounds, so a tote is over two tons. So if they've shipped just one... it's tons.
PCTL ships 5000 gallons per truck load.
So to keep it simple if PCTL gets $8.00 a gallon then each truckload will be $40,000.
Two 10,000 gallon orders was shipped to the customer in the PR above with recurring orders to follow.
PCTL was on the verge of financial meltdown and HOCI gave it not only a lifeline but major financial surgery. It stop the bleeding and infused with some blood to the point it has been discharge and will recover fully. It will take some time however it is moving in the right direction in the middle of a pandemic.
PCTL is making money and growing it's business in the middle of a pandemic.
The stock price is not reflective of PCTL's transformation and may not be until the 2nd quarter financials come out.
That was so funny!!!
I have to save those figures for future reference.
I can't stop laughing.
Liquid Gold Carolina Tea I just can’t wait to see what PCTL has in store for me.
10K late make no mistake it does matter so why all the chatter
The company a moving due to the infusion of cash flowing and clients growing
Lighten up and don’t worry too much all is well and maybe the 10K will drop after the bell
Liquid production March 15th -June 30th. ……. Sound correct?
max (3 shifts 7 days /wk)
106 shifts@ 14000gals/shift=1,484,000gal @ $8.00/gal=$11,872,000
Cost labor average 20.00/hrx 2544hrs=$50,880
min (1 shift 5days /wk)
78 shifts@14000gals/shift=1,092,000gal @ $8.00/gal=$8,736,000
Cost labor average 20.00/hr x 624 hrs=12,480
360x3=1080 shifts/yr x 14,000 gal/shift=15,120,000 x $8.00/gal= $120,960,000 / yr
Income on liquid only.
Are we wo Unit production 25/mo in S.C. 25/mo in Ft Wayne=50/mo starting July through Dec=300 units @ 8,000 / mo lease for 6 mos=$ 14,400,000
Est 14 units in NYC
2 units in UK
5 units some where= 21 units @ $8,000/unit=168,000/mo x 12mo=$2,016,000
$2,016,000+$14,400,000=$16,416,000
PCTL is in a great position to disrupt the market share of contracts for Infection Control Systems with Healthcare and other industries.
Why did they focus on Healthcare first?
Hospital Disinfectant Products Market to Expand at Growth Rate of ~ 5.3% CAGR from 2018 to 2026 to Reach US$ 17.1 Billion through 2026:
https://www.prnewswire.com/news-releases/hospital-disinfectant-products-market-to-expand-at-growth-rate-of--5-3-cagr-from-2018-to-2026-to-reach-us-17-1-bn-through-2026-transparency-market-research-300999388.html
PCTL has the best solution to a multi-billion dollar problem.
Introducing the Most Technologically Advanced Disinfection System Ever Created to Eliminate Hospital Associated Infections (HAIs) using Patented RFID Technology for Tracking and Disinfecting Protocols.
Annihilyzer: A New Disruptive Technology in the World of Hospital Disinfection
Why is the Annihilyzer Infection Control System one of the best and most versatile in the world ?
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
What can the Annihilyzer do?
Save time and money by generating disinfectant and all-purpose cleaner on-site, on-demand
Eliminate the toughest bacteria, viruses, and fungi, including C. diff, C. auris, MRSA, VRE, blood-borne pathogens, and more.
Create 'industry best' protocols and 'push' them out to your cleaning staff in real-time with the Annihilist dashboard and mobile app
Generate reports that show when the areas were cleaned, who cleaned them, and what was done
Increase staff efficiency and effectiveness with process tracking, training, and accountability
How does the Annihilyzer save companies money?
Costs associated with purchasing and managing chemicals – eliminated
Freight charges for chemical deliveries – eliminated
Chemical container disposal or recycling costs – eliminated
Personal protection gear for cleaning – eliminated
Wastewater disposal costs and related fines for non-compliance – eliminated
Workers comp claims due to chemical burns and fume inhalation – eliminated
Happier, healthier and more productive workers
Same or better cleaning power than traditional hazardous chemicals for less
Eliminates costs associated with ordering, inventorying and disposing of chemicals and containers
Versatile
Grieco added: “All of our hospital customers using our infection control system and disinfectant are utilising the systems as a front-line defence throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors.”
What other Infection Control System can do that?
What other system can provide a disinfectant and cleaner?
Results
Why would a hospital sign a 5-year agreement with PCTL when they could have signed a 2 or 3 year agreement?
I'll tell you why - RESULTS RESULTS RESULTS
SUNY Downstate Medical Center chose to renew their contract with the Company for an additional five years after utilizing the system for one year.
What are the chances at some point in the future when the other SUNY hospitals (Syracuse and Stony Brook) Infection Control Contracts expire that they sign with PCTL?
Why has every hospital that went through the 60 day trial period decided to do a multi-year contract? I'll tell you why - RESULTS RESULTS RESULTS
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
Most Technologically Advanced Disinfection System Ever Created
Annihilyzer the future for Healthcare and other Industries
During the Coronavirus Pandemic a Hospital with the Annihilyzer in place was in a better position than a hospital without it. Many hospitals will be asking themselves what could we have done differently? If they know about the Annihilyzer, having one will certainly be one of their answers. This is not the last so they have to put themselves in the best position for future events.
Where else can you get TWO products for the price of ONE
What is a better investment for a whole room Infection Control System:
Annihilyzer versus an UV system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Also the Annihilyzer cost less than half that of one of the best UV system on the market, the Xenex “LightStrike” cost about $125,000,
Annihilyzer versus a Chemical (Hydrogen Peroxide) based system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Chemical based solutions require protective equipment, are more expensive and are harsh on furniture and one company called Hanosil sells their machine for under $10,000 however it costs $20 in product to clean each room.
The ultimate goal for PCTL is to sell/lease lots and lots of their flagship product, the "Annihilyzer".
From the Stock Podcast dated May 8, 2020:
Additional hospital installations of PCT Corp.’s Annihilyzer® Infection Control Systems are expected to continue throughout the end of the month and into the summer.
“Our fluid sales and distribution activities have helped facilitate growth and business expansion,” explains CEO Gary Grieco. “With our hospital installations now on track as well, we’re full steam ahead on multiple fronts. It’s a very serious, but exciting time for us.
From the Stock Podcast dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
Grieco then addressed rumors that the Company is expanding into China. Grieco shared that the Company signed an MOU in January of 2020, which required the Company to deliver systems. “When the pandemic broke, we took that out of the equation,” said Grieco. “What we have done is tabled any discussions until late summer,” he continued. “I don’t feel that we should be shipping any systems anywhere as long as we need them here in the United States.”
If they are going to start with five systems to the UK who are the other 20 systems for?
There is information we just don't know about yet.
It is my belief that during the run on HOCI, PCTL got some orders for Annihilyzers and I believe those machines are going somewhere in America.
From the Press Release dated April 16, 2020:
The company continues to expand domestically as well. Following an earlier release dated April 14th , the company is also announcing an additional purchase order for PCT Corp.’s Annihilyzer® Infection Control Systems in New York City.
“With three PO’s for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases,” says Grieco. “We are on pace for unprecedented and record growth in all areas of our business.”
From the Press Release dated April 14, 2020:
The company believes that once the current travel restrictions are lifted, they will be able to continue their plans for accelerated placements of Annihilyzer® systems in New York City and elsewhere. “We have a number of interested parties in our sales pipeline,” adds Grieco.
From the Press Release dated April 7, 2020:
The company has also been hiring additional support staff to support growing business operations. Most recently, the company engaged Joseph Tippmann, graduate of The University of Michigan’s Industrial Design and Architecture program, as a new design engineer. Tippmann joined the company on a contract basis initially and has spent the past two weeks performing design updates on Annihilyzer and Hydrolyte Rack systems in addition to helping design a more modular system for easier assembly.
Werks Manufacturing is expanding their operation and will increase parts and assembly production to meet PCTL’s growing demand. In addition, Werks will also serve as a fluid depot for PCTL’s clients in the northern Midwest part of the United States.
From the Press Release dated March 25, 2020:
PCTL is continuing to expand business operations at a rapid rate while experiencing a dramatic increase in inquiries and orders from new and existing clients.
“The demand for our products has been nothing short of explosive,” explains CEO Gary Grieco. “Due to this high demand, we are shifting our focus, in the short term, towards fluid production, sales, and distribution.”
Jody Read, COO stated: “We are still continuing to see significant interest in the facility-based Annihilyzer® Infection Control System. However, we are not able to coordinate installations due to travel restrictions and availability of hospital staff to implement the systems. We are continuing to build systems and at the same time utilize our current South Carolina facility’s capabilities with large volume systems to produce mass quantities of disinfectant for distributors and hospitals.
The Annihilyzer® Infection Control System remains the company’s flagship product and continues to garner intense interest from prospective hospitals and healthcare facilities.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
Also while all this was going on there was an unprecedented demand for Infection Control Systems worldwide that couldn't be met.
https://www.forbes.com/sites/richblake1/2020/04/17/in-covid-19-fight-robots-report-for-disinfection-duty/#14cbcc722ada
Large-scale coronavirus testing continues to lag and a vaccine could be at least one year away. But in the battle against world pandemic a rapidly expanding brigade of robots is answering an urgent call of duty: surface disinfection.
They're rolling in by the hundreds and not just into hospitals and nursing homes but across a wide spectrum of public spaces, including government buildings, offices, hotels, airports and universities. Administrators of all stripes, desperate to keep people safe, are looking to a global robotics industry that has been quick to respond.
"Hospitals around the world are waking up to autonomous disinfection," Nielsen said. "We can't build these robots fast enough.
"Healthcare-sector suppliers like UVD, Xenex and others still are a long way from being able to meet exploding global demand for automated disinfection solutions but it's not just specialized service robots riding into battle.
Let us connect some dots:
1. Hypochlorous Acid sales through the roof.
2. Demand for Infection Controls Systems exploding.
If you are in need of Hypochlorous Acid and an Infection Controls Systems where do you go.
There are many companies that sell Infection Controls Systems.
There are many companies that sell Hypochlorous Acid.
There are very few companies besides PCTL that can give both in one system.
I would be shocked if PCTL didn't get many orders for their system based on the demand for their products.
Two for the Price of one.
FACTS not fiction
Interesting.....Timely.....Accurate.....
PCT, LTD et al v. Paris et al
https://dockets.justia.com/docket/north-carolina/ncwdce/3:2020cv00287/100313
Selling a patent allows the inventor to generate income that will help pay the bills or finance other promising ideas. Selling a patent outright also eliminates the huge financial outlay required to start up a business based on a new product.
On April 6, 2017, the Company acquired intangible assets by issuing 2,250,000 shares of common stock at a deemed value of $1.96 per share ($4,405,050) to Annihilyzer Inc. in order to close on the amended agreement dated April 6, 2017. Pursuant to the terms of the Agreement, as amended,the Company acquired an Annihilyzer patent and all associated intellectual property. In addition, Paradigm granted Annihilyzer Inc, a three-year license and sub-registration under Paradigm’s EPA Product Registration #82341-4. Annihilyzer, Inc. had no activity under this sub-registration agreement as of December 31, 2017.
On July 30, 2019 the Company accepted a settlement proposal from Annihilare, Inc. (a sub-registrant of the Company’s US EPA Registration No. 92108-1) and its affiliated company, Prime ITS (a prior owner of Annihilyzer Inc, which transferred previously noted intangible IT assets to PCT LTD for 2,250,000 shares of the Company’s common stock in November of 2016). The settlement agreement included credit to the Company by Prime ITS in the gross amount of $23,209 on the Company’s payable to Prime ITS for a combination of a portion of Marty Paris’ salary, a resignation from Marty Paris effective July 31, 2019, and equal valued amount of PCT’s inventory, for net credit to PCT in the amount of $13,939, which was received by the Company on July 31, 2019. The transaction was completed on August 1, 2019.
On August 8, 2019, we received notice from Annihilare, Inc. that certain intellectual properties developed jointly between us and Annihilare are to be discontinued from use by us and our customers. We dispute the claims from Annihilare that the intellectual properties are exclusively Annihilare’s and are in discussions with Annihilare on this point. We have engaged counsel to assist us with this dispute and are evaluating potential litigation on this matter. However, as of the date of this filing no litigation has been initiated.
On August 8, 2019 the Company received notice from PRIME ITS that certain technology services utilized by the Company shall cease to be provided, effective September 8, 2019.
On August 8, 2019 the Company received notice from Annihilare, Inc. that certain intellectual properties developed jointly between the Company and Annihilare are to be discontinued from use by the Company and our customers. We dispute the claims from Annihilare that the intellectual properties are exclusively Annihilare’s and are in discussions with Annihilare on this point.
When a court finds infringement, the infringer usually must pay damages to the patent holder, either in the form of actual damages or a reasonable royalty for the unauthorized use. ... The court typically, as a matter of course, issues a permanent injunction after the infringer is held liable for violating the patent.
In general, you can determine if you have infringed a patent by checking if your product or service performs all the steps and has all the structure described in at least one of the independent claims. Since these are the broadest claims, you must have at least those details in your product to infringe.
A U.S. utility patent, explained above, is generally granted for 20 years from the date the patent application is filed; however, periodic fees are required to maintain the enforceability of the patent. A design patent is generally granted protection for 14 years measured from the date the design patent is granted.
I was just thinking outside the box with what the company is saying and what is going on outside the company and trying to put draw a reasonable conclusion.
If somebody wanted a Infection Control System and they couldn't get it for company A,B or C they are going to keep looking if they really want it.
Another thing with the selling of the HOCI, there had to be conversations out there from truckers, distributors and others that led to phone calls back to the PCTL.
There is a lot on info that we just don't know about.
Why do you think those 25 Annihilyzers are for the UK.
PTCL never said where those machines are to be delivered.
From the Stock Podcast dated April 21, 2020:
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
Jolly then commented on the Company’s latest press release detailing a distribution agreement with the UK NHS company. Grieco shared that the agreement will likely begin with five systems starting in July and will later expand to fulfill the needs of their healthcare system.
If they are going to start with five systems to the UK who are the other 20 systems for?
There is information we just don't know about yet.
It is my belief that during the run on HOCI, PCTL got some orders for Annihilyzers and I believe those machines are going somewhere in America.
Also while all this was going on there was an unprecedented demand for Infection Control Systems worldwide that couldn't be met.
https://www.forbes.com/sites/richblake1/2020/04/17/in-covid-19-fight-robots-report-for-disinfection-duty/#14cbcc722ada
Large-scale coronavirus testing continues to lag and a vaccine could be at least one year away. But in the battle against world pandemic a rapidly expanding brigade of robots is answering an urgent call of duty: surface disinfection.
They're rolling in by the hundreds and not just into hospitals and nursing homes but across a wide spectrum of public spaces, including government buildings, offices, hotels, airports and universities. Administrators of all stripes, desperate to keep people safe, are looking to a global robotics industry that has been quick to respond.
"Hospitals around the world are waking up to autonomous disinfection," Nielsen said. "We can't build these robots fast enough.
"Healthcare-sector suppliers like UVD, Xenex and others still are a long way from being able to meet exploding global demand for automated disinfection solutions but it's not just specialized service robots riding into battle.
Let us connect some dots (2 dots):
1. Hypochlorous Acid sales through the roof.
2. Demand for Infection Controls Systems exploding.
If you are in need of Hypochlorous Acid and an Infection Controls Systems where do you go.
There are many companies that sell Infection Controls Systems.
There are many companies that sell Hypochlorous Acid.
There are very few companies besides PCTL that can give both in one system.
I would be shocked if PCTL didn't get many orders for their system based on the demand for their products.
Two for the Price of one.
FACTS not fiction
Interesting.....Timely.....Accurate.....
No 10K yet
No problem
Temporary situation
PCTL is an emerging company that overcame great hurdles to bring their flagship product to the marketplace.
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
The fact that they are late with the 10K is minor as compared to them generating cash flow and growing the company.
What lasting effect does a late 10K have on a company?
None
While it is disappointing that the 10K wasn't filed today, I trust that the company is doing everything humanly possible to get it out soon. It is just a TEMPORARY situation. We are in the midst of a worldwide pandemic with over 100,000 deaths in the US. Our auditor, Sadler, Gibb & Associates, LLC has been with the PCTL since 2015 so our previous information should be on file.
Be thankful that our company was able to operate during the pandemic and help fight this devastating virus.
Sadler, Gibb & Associates, LLC
2455 E Parleys Way,
Salt Lake City, UT 84109
FACTS not fiction
P.S. I still intrigued about delivering 25 systems a month.
Deliver to whom?
How many months?
I believe all what PCTL is working on will be revealed at the appropriate time.
We don't know the details however based on the past PCTL press releases, podcasts and interviews they tell us what they are plan on doing, they do it and then they tell us what they did.
It will all come out in the future filings.
It was just 2 years ago when PCTL installed their first Annihilyzer in a hospital.
In the last 18 months they have at least one system installed in twenty percent of the hospitals in New York City.
Many hospitals don't even use a whole room infection control system.
I believe with the arrival of the pandemic these hospitals may consider getting one.
There are a lot of unknowns and for a good reason.
It serves a business well to operate with unnecessary information in the public realm as to grow without the competition trying to out maneuver you.
Sometimes less is better.
Stock prices always responds to the fundamentals of a company whether good or bad.
First off the 10K is going to be uninspiring.
All other reports to follow will get better and better.
What we do know is the company was selling HOCI at an unprecedented rate to the point of record sale and revenues.
We don't have the numbers however based of the press releases they should be significant.
For me the biggest mystery is why the CEO says PCTL has a need to DELIVER 25 ANNIHILYZERS a month starting in July.
Who is the contract from and how big is it?
How many months do they need to deliver 25 systems?
HUGH simply HUGH!!!!
People are invested in PCTL because it is an emerging company with HUGH potential.
How could a company go from needing an “angel funder” with 3.5-5 million dollars to invest to record sales for the quarter and profitable for the month of March 2020 all in a week’s time?
I’ll tell you how HOCI!!!!
The question now is do they still need the 3.5-5 million dollars?
Do they have that 3.5-5 million dollars lined up due to their sudden windfall?
Don’t know
Thoughts
It has a record breaking Q1 for sales and revenues.
PCTL is a growing company and although it went through some toxic financing, they were fortunate enough to increase sales due to an unprecedented demand for HOCI that put them in a position to cover their burn rate. Also 2019 is the year where PCTL had the most system installs that will most likely increase exponentially in 2020.
PCTL revenues increased year to year with the biggest bump up in 2019. Please note the revenues for 2019 are just through the 3rd quarter as the 2019 10K has not been filed yet.
2015 $141
2016 $113,387
2017 123,105
2018 $266,122
2019 $534,852 thru 9 months
2020 $$$$$$$$$$$$$$
2021 $$$$$$$$$$$$$$$$$$$$$$
2022 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
From the March 9, 2020 CEOCFO Magazine interview:
CEOCFO: Are you funded now? Are you seeking partnership, investments or funding as you move forward?
Mr. Grieco: Yes. Obviously, for a small company, that has been our greatest, most stubborn obstacle! First of all, the length of time that it takes to get into hospitals, and second of all, the length of time; even once you make your first presentation, the average time is about six months before you get them to agree to a Phase I Installation! Those things are very costly for us to provide. We are sending in our own Infection Preventionist, former Hospital EVS Administrator and our Technical Engineer to discuss our system, the fluid side itself and on how all the machines operate; that’s expensive. Therefore, yes! We are certainly looking for funding now; I guess the correct term would be an angel funder, from this point. Someone who understands what we do, sees its impact on the healthcare system of this country, sees its impact on a company that can deliver a solution to that and is willing to commit three and one half to five million dollars to that process.
From the PR dated March 13, 2020:
As a result of increased demand, an existing customer, BioBlasting LLC of Egg Harbor Township, New Jersey (www.bioblasting.com) has also purchased two of PCT Corp.’s large volume Hydrolyte® generators.
"Our company has been growing exponentially over the past 2 years as our clients have discovered the benefits of our fluid solutions, which offer a high level of safety for both staff members and the general public," says BioBlasting CEO, Arthur Handson. "In light of the recent outbreak, our team has been working around the clock to ensure our products are accessible to all people and industries, particularly schools. Our goal is to minimize the effects of infectious disease outbreak by implementing proper preventive measures as well as assisting with eradication procedures as needed."
"We’ve had a great relationship with BioBlasting for over two years," says PCT LTD CEO, Gary Grieco. "As an existing sub-registrant, they have seen firsthand the safety and efficacy of our product. We’re happy to take this next step with them and excited to support them in their growth and efforts to serve their customers and communities."
As a result of heightened demand, PCT Corp. is expediting plans to increase its distribution networks. "With everything going on in the world today, our demand has increased by leaps and bounds" says PCT Corp. President, Bill Prince. "Adding key distributors to our network will allow us to strengthen sales channels and accelerate revenue growth while at the same time providing a much-needed product and service during these critical times. We will strategically add additional distributors and "partners," both In the United States and abroad. This will allow us to keep up with the strong need for our products."
From the March 16, 2020 Stock Day Podcast:
“How do you view the short to medium term of your company’s sales going forward?”, asked Jolly. [color=blue][/color]Grieco shared that the Company remains undervalued considering the effectiveness of their hypochlorous disinfectant system, which is now entering its ninth hospital. [/color]“I think that one of the big problems with any small company is profitability,” said Grieco, “I will go out on a limb and say that we will be profitable in the month of March. We will have a record first quarter,” shared Grieco. “I think this month will set a stage,” he added.
“I am more optimistic than I’ve ever been with this company, and I’ve been involved with this kind of technology since 1996,” closed Grieco.
Opportunity fell on their doorstep and they took full advantage of it.
PCTL is a stock with the right product at the right time.
PCTL to the Moon and Beyond!!!
BOOYAH
The information that will be reflective on the 10k is mostly already known from what was reported on the last quarterly dated 4/13/2020 minus companies operations for the 4th quarter. The 2020 1st quarter report should show the company transitioning as a company on a cash flow basis to cover the burn-rate. The 2nd quarter report should show significant cash flow and an explosive growth not only for fluid sales but Annihilyzers systems as well. If all what PCTL management have been reporting in recents months is true and I don’t doubt them, then the company is in a great position to grow, become financially stable and prepare themselves to move to another exchange.
The day to day stock price is just the market makers doing their job and the stock price will move up and down based on the results (fundamentals) of the company. When the results are fully realized in the future reports especially starting with the 2nd quarter report then it will be reflected in the stock price. Also Press releases, podcasts, and other media outlets may influence the stock price movement.
“I’ve been called Mr. Patient Money because I have the patience to work through challenging circumstances.” – N. Murray Edwards
PCTL 4th quarter events:
PCT LTD Issues Company Update and Announcement of Collaborative Agreement for Oil & Gas and Cannabis Applications
PCT LTD Deploys Initial Annihilyzer® Infection Control System to the United Kingdom
PCT LTD Continues to Expand by Signing Long-Term Agreement with ACE
PCT LTD Announces Additional Hospital Installation of Annihilyzer® Infection Control System
From the 3rd quarter 10Q:
Common Stock
On January 28, 2019, the Company agreed to convert $131,327 of principal and interest of the notes payable described in Note 6(a) into 987,421 shares of the Company’s common stock.
On March 25, 2019, the Company issued 200,000 shares of common stock to two employees of the Company as compensation in lieu of commission on sales of the Company’s products. The Company recorded the fair value of the common shares of $34,000 in consulting expense.
On March 29, 2019, the Company executed a settlement agreement with a contractual consultant, UCAP Partners, LLC for the settlement of $25,000 owed to the contractor for the provision of services as related to the March 15, 2018 agreement between UCAP and us. The settlement terms include acknowledgement that the Company owes UCAP $25,000 as payment for said services; that UCAP purchased and fully paid for Series A Preferred Stock and Warrants from the Company on December 3, 2018 (100,000 Preferred Series A Shares and 100,000 warrants to purchase common shares at $0.10/share); the settlement is outlined as follows: the Company shall issue 164,000 shares of its common stock as payment in full for the services rendered on the consulting contract; the Company shall accept UCAP’s conversion and exercise of the purchased 100,000 Preferred Series A shares into 100,000 shares of the Company’s common stock and the Company shall accept the cashless conversion of UCAP’s 100,000 warrant into 34,400 shares of the Company’s restricted common stock; and, as inducement for and consideration for the settlement of the Company’s debt to UCAP, the Company agrees to grant 500,000 additional shares of the Company’s restricted stock. As a result During the nine months ended September 30, 2019, the Company issued a total of 4,999,000 shares of the Company’s common stock upon the conversion of $2,196 of principal and $953 of interest pursuant to the convertible note payable described in Note 6(o).
During the nine months ended September 30, 2019, the Company issued a total of 5,555,555 shares of the Company’s common stock upon the conversion of $5,000 of principal pursuant to the convertible note payable described in Note 6(p).
of this transaction, 3,597,989 shares of Company’s common stock were issued and a $55,830 loss on settlement of debt was recognized.
During the nine months ended September 30, 2019, the Company issued a total of 76,154,631 shares of the Company’s common stock upon the conversion of $44,723 of principal ($42,223) and interest ($2,500) pursuant to the convertible note payable described in Note 6(i).
During the nine months ended September 30, 2019, the Company issued a total of 66,290,000 shares of the Company’s common stock upon the conversion of $64,558 of principal ($58,058) and interest ($6,500) pursuant to the convertible note payable described in Note 6(j).
During the nine months ended September 30, 2019, the Company issued a total of 18,559,816 shares of the Company’s common stock upon the conversion of $74,200 of the convertible note payable pursuant to the convertible note payable described in Note 6(k).
During the nine months ended September 30, 2019, the Company issued a total of 5,207,600 shares of the Company’s common stock upon the conversion of $4,508 of the convertible note payable and $179 of accrued interest pursuant to the convertible note payable described in Note 6(m).
During the nine months ended September 30, 2019, the Company issued a total of 7,500,000 shares of the Company’s common stock upon the conversion of $8,640 of principal pursuant to the convertible note payable described in Note 6(n).
During the nine months ended September 30, 2019, the Company issued a total of 3,054,511 shares of the Company’s common stock upon the conversion of $13,000 of principal pursuant to the convertible note payable described in Note 6(q).
During the nine months ended September 30, 2019, the Company issued a total of 11,490,000 shares of the Company’s common stock upon the conversion of $27,804 of the convertible note payable and $5,287 of accrued interest pursuant to the convertible note payable described in Note 6(s).
On August 16, 2019, the Company issued 5,989,500 shares of common stock upon the cashless exercise of 6,000,000 warrants.
On September 24, 2019, the Company issued 6,041,381 shares of common stock upon the cashless exercise of 6,057,143 warrants.
On August 1, 2019, the Company entered into a consulting agreement for investor relations services through September 30, 2019. The agreement called for 1,000,000 restricted shares of common stock to be issued to the consultant. As of September 30, 2019, the Company recorded $15,000 in additional paid-in capital for the consulting expense related to the consulting services provided, due to the fact that the 1,000,000 common shares were issued subsequently on March 11, 2020.
NOTE 10 – WARRANTS
As described in Note 6, from February 14 through September 11, 2019, the Company issued 487,500 warrants subject to an exercise price of $0.20 per share for 5 years and 300,000 warrants subject to an exercise price of $0.10 per share for 5 years. If the Company issues any common stock or common stock equivalents at an effective price per share less than the warrant’s exercise price the exercise price of the warrants will be reduced to the lower price. In addition, the number of common shares issuable upon conversion of the warrants is increased so that the number of shares issuable multiplied by the exercise price equals the aggregate exercise price of the warrants immediately prior to the exercise reduction. During period, convertible notes were exercised at a price less than the original exercise price of these warrants, resulting in an adjustment to the number of warrants and exercise price.
NOTE 13. SUBSEQUENT EVENTS
On October 1, 2019, the Company entered into a consulting agreement for investor relations services through March 31, 2020. The agreement called for a cash payment of $25,000 and 12,000,000 restricted shares of common stock to be issued to the consultant. The Company issued the 12,000,000 common shares to the consultant on March 16, 2020.
On October 3, 2019, the Company entered into a promissory note with a non-related party for $50,000. The note is due on April 3, 2020 and bears interest at a rate of 12%. On October 9, 2020, the Company had repaid $12,599 of the loan. On March 8, 2020, the Company agreed to settle the remaining $39,054 of principal and accrued interest outstanding on the note through the issuance of 39,000 Shares of Series A Preferred Stock and the payment of $54.
On October 4, 2019, F. Jody Read stepped down from his position as Chief Executive Officer of the Registrant due to increased workload in the Registrant’s wholly-owned operating subsidiary. Mr. Read remains as a director and Chief Operating Officer of the Registrant. Concurrent with Mr. Read stepping down from the position of Chief Executive Officer, the Registrant appointed Mr. Gary J. Grieco to act as President and Chief Executive Officer of the Registrant.
On October 7, 2019, the Company entered into a convertible promissory with a non-related party for $53,000 of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $50,000. The note is due on October 7, 2020 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note’s term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date.
On October 8, 2019, the Company issued 6,399,302 shares of common stock upon the cashless exercise of 6,424,286 warrants.
On October 22, 2019, the Company issued 6,498,105 shares of common stock upon the cashless exercise of 6,528,571 warrants.
On October 29, 2019, the Company entered into a convertible promissory with a non-related party for $50,000 of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $47,000. The note is due on October 29, 2020 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note’s term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date.
On November 12, 2019, the Company entered into a promissory note with a non-related party for $17,500. The note is due November 12, 2020, is unsecured and bears an interest rate of 8% per annum.
On December 12, 2019, the Company entered into a loan with a non-related party for $12,250 of which $2,250 was the loan fee or original issue discount resulting in cash proceeds to the Company of $10,000. The note is to be repaid through 12 monthly payments ending on May 12, 2020.
On December 19, 2019, the Company sold future receivables of $83,400 in consideration for $58,200. The advance is to be repaid through $3,208 weekly payments. In connection with the advance, the Company granted the lender a security interest in all accounts, equipment, intangibles and inventory.
On December 20, 2019, the Company sold future receivables of $148,362 in consideration for $100,000. The advance is to be repaid through $2,958 weekly payments.
On December 31, 2019, the Company sold future receivables of $87,540 in consideration for $60,000. The advance is to be repaid through $3,651 weekly payments. The Company paid $3,625 of finance fees and includes default fees of up to $2,500 and a default rate of interest of 9%. In connection with the advance, the Company granted the lender a security interest in all accounts, equipment, intangibles and inventory. As of the date of filing the Company had only received advances of $15,575.
From October 1, 2019 through March 25, 2020, the Company issued a total of 265,453,351 shares of common stock upon the conversion of $286,043 of principal, $20,306 of interest and of fees pursuant to the convertible notes payable described in Note 6.
Liquidity and Capital Resources
A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.
At September 30, 2019, the Company recorded a net loss for the nine month period of $10,214,462 and had a working capital deficit of $8,934,741. We have recorded revenues from operations, but these have been insufficient to cover our operating costs. During the nine months ended 2019 and 2018 we have primarily relied upon advances and loans from stockholders and third parties to fund our operations. The Company has relied on raising debt and equity capital in order to fund its ongoing day-to-day operations and its corporate overhead. We had $6,669 in cash at September 30, 2019, compared to $4,893 in cash at December 31, 2018. We had total liabilities of $9,097,175 at September 30, 2019 compared to $3,141,401 at December 31, 2018.
Our current cash flow is not sufficient to meet our monthly expenses of approximately $210,000 and to fund future research and development. We intend to rely on additional debt financing, loans from existing stockholders and private placements of our securities for additional funding in addition to the increasing our recognized revenue from the leasing and/or sale of products; however, there is no assurance that additional funding will be available. We do not have material commitments for future capital expenditures. However, we cannot assure you that we will be able to obtain short-term financing, or that sources of such financing, if any, will continue to be available, and if available, that they will be on favorable terms.
PCTL emerging from toxic financing to profitabilty.
The story of PCTL is about a little company trying to develop and introduce state of the art technology across different industries including healthcare, oil and gas, food services and agriculture. To truly see the evolution of PCTL one should follow the numbers and the place to start is the FINANCIALS. What does one see?
PCTL shares increased year to year with an enormous bump up in 2019 due to toxic financing. The company was selling shares to support operations.
PCTL revenues increased year to year with the biggest bump up in 2019. Please note the revenues for 2019 are just through the 3rd quarter as the 2019 10K has not been filed yet.
What does this all mean?
PCTL is a growing company and although it went through some toxic financing they were fortunate to increase sales due to an unprecedented demand for HOCI that put them in a position to cover their burn rate. Also 2019 is the year where PCTL had the most system installs that will most likely increase exponentially in 2020.
The story of PCTL is changing daily. FACTS not fiction.
Below are some excerpts from recent filings, followed by some excerpts from press releases. People will try and oppose what is FACT with their fiction which is just not possible.
From the 2016 10K dated 4/14/2017
The number of shares outstanding of the registrant’s common stock as of April 14, 2017 was 37,542,572.
Revenues increased to $113,387 for the year ended December 31, 2016 compared to $141 for the year ended December 31, 2015. The revenue increases for 2016 were due to the increased volume of fluids sold and the sale of a piece of fluid producing equipment.
Research and development expenses increased to $147,917 for the 2016 year compared to $29,871 for the 2015 year. Research and development expenses increased for 2016 due to field testing required for EPA certification.
From the 2017 10K dated 4/17/2018
We had 204 stockholders of record as of April 17, 2018 and 43,409,238 shares outstanding. We have not declared dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future.
Revenues increased to $123,105 for the year ended December 31, 2017 compared to $113,387 for the year ended December 31, 2016. The revenue increases for 2017 were due to the increased volume of fluids sold, the sale of a piece of fluid producing equipment, licensing revenue from EPA sub registration, and placing equipment under the Company’s 2-year Systems Service Agreement (“lease”) in December, 2017.
Research and development expenses increased to $315,385 for the 2017 year compared to $147,917 for the 2016 year. Research and development expenses increased for 2017 due to testing of the application of the Hydrolyte® technology in the oil and gas industry; as a biocide in institutional facilities, such as, hospitals, jails and medical facilities; and in agriculture and food processing.
From the 2018 10K dated 4/15/2019:
The number of shares of the Registrant’s common stock outstanding as of April 12, 2019 was 51,643,048.
Revenues increased to $266,122 for the year ended December 31, 2018 compared to $123,105 for the year ended December 31, 2017. The revenue increases for 2018 were due to the increased volume of fluids sold, the sale of a piece of fluid producing equipment, licensing revenue from EPA sub registration, and placing equipment under the Company’s 2-year Systems Service Agreements (“leases”).
From the 2019 3rd 10Q
The number of shares outstanding of the registrant’s common stock as of April 10, 2020 was 527,813,393 which does not include 427,186,607 shares of common stock reserved against default/conversion of convertible debt.
Revenues increased to $534,852 for the nine months ended September 30, 2019 compared to $153,337 for the nine months ended September 30, 2018. The revenue increase for the period was due to the increased volume of fluids sold, the sale of a duplicate US EPA Registration, licensing revenue from EPA sub registrations, equipment sales and the additional revenue from recurring leased-equipment income.
PCTL emerging from toxic financing to profitabilty.
Paradigm Convergence Technologies Corp (PCT) is a technology licensing company specializing in environmentally safe solutions for global sustainability. The company provides innovative products and technologies for eliminating contamination from water supplies, industrial fluids, hard surfaces, food processing equipment and medical devices.
PCTL launched its flagship product, Annihilyzer® Infection Control System that is designed to help alleviate the growing problems of Hospital Acquired in May 2018.
https://www.para-con.com/images/docs/PCTL5-16-18.pdf
PCTL successfully installed the PCT Annihilyzer® Infection Control System at Johnston UNC Health Care Hospital, in Smithfield, North Carolina in May 2018.
https://www.para-con.com/images/docs/PCTL5-18-18.pdf
PCTL provided with sufficient independent laboratory AOAC efficacy testing data to support PCT claims that our Hydrolyte® product is effective in killing a broad range of microbial pathogens, including C-Diff, TB, HCV, HIV-1, CRE, VRE and MRSA, as well as other bacteria and viruses, qualifying Hydrolyte® as a hospital-level disinfectant in May 2018.
https://www.para-con.com/images/docs/PCTL5-22-18.pdf
PCTL is increasing production capacity in response to expected demand for its Annihilyzer® Infection Control Systems and Large Volume Systems in May 2018. Current sustainable single shift capacity of the facility is 20 to 25 units per month, which can be increased to 40 to 50 units per month with additional production personnel and shifts.
https://www.para-con.com/images/docs/PCTL5-29-18.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions for global sustainability announced today it has entered into a license and distribution agreement with a long established agricultural chemical company. The one-year exclusive agreement, subject to renewal, provides for license fees and monthly royalty and equipment leasing payments in September 2018.
https://www.para-con.com/images/docs/PCTL-9-26-18.pdf
PCTL announced today it has entered into a Master Services Agreement with a New Yorkbased hospital supply and services company for the installation of two Annihilyzer® Infection Control Systems to prevent hospital-acquired infections (HAI’s) in hospitals in its market area in October 2018.
https://www.para-con.com/images/docs/PCTL10-25-18.pdf
PCTL announced today that, with its New York-based representative, it has entered into a contractual agreement for the installation and operation of two Annihilyzer® Infection Control Systems in a major Brooklyn hospital in November 2018.
https://www.para-con.com/images/docs/PCTL11-01-18.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions for infection control, secured a three-year Master Service Agreement and recently installed its Annihilyzer® Infection Control System at Carson Tahoe Regional Medical Center in Carson City, NV.
https://www.para-con.com/images/docs/PCTL-01-10-19.pdf
PCTL, a leader in environmentally safe, nontoxic, antimicrobial solutions for infection control, announced today it has entered into a Manufacturer’s Representative Agreement with DTS of Cleveland, OH (DTS), for the sale of Annihilyzer® Infection Control Systems in Ohio, West Virginia, Western Pennsylvania, Michigan, Indiana and Kentucky.
https://www.para-con.com/images/docs/PCTL-02.07.19.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions announced today it has received a repeat order for two large volume Hydrolyte® Systems from one of its existing food processing customers. The referenced food processing customer’s plant currently has two systems at one facility and purchased another large volume system from PCT as a result of their 2018 plant expansion.
https://www.para-con.com/images/docs/PCTL-02.12.19.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions announced today it has sold and is currently installing a large volume C-104 Hydrolyte® Systems to an existing customer, H2S Safe Treat, Inc. of Ada, OK (H2S).
https://www.para-con.com/images/docs/PCTL-02.25.19.pdf
PCTL, announced today that ACE Janitorial Supply Company (“ACE”), PCT Corp.’s distributor for the New York hospital and healthcare market, received a new purchase order for Morgan Stanley Presbyterian Children’s Hospital to continue using PCT Corp.’s patented Annihilyzer® Infection Control System following a successful 60-day trial within the facility.
https://www.para-con.com/images/docs/PCTL5-06-19.pdf
PCTL, announces another successful phase one installation of PCT Corp.’s Annihilyzer® Infection Control System in coordination with its primary healthcare distributor, ACE Janitorial Services. PCT Corp.installed the premier cabinet model of its Annihilyzer® Infection Control System this week at Mount Sinai South Nassau Medical Center located in Oceanside, NY.
https://www.para-con.com/images/docs/PCTL10-07-19.pdf
PCTL, a Little River, South Carolina company and the designer of the Annihilyzer® Infection Control System, a world class whole room cleaning and disinfecting system for hospitals and health care facilities, is pleased to announce that it has shipped the first overseas Annihilyzer® Infection Control System to its partner company, PCT Europe Ltd., in the United Kingdom.
https://www.para-con.com/images/docs/PCTL10-22-19.pdf
Most recently, PCTL Environmental Solutions, Inc. (“AES, Inc.”) of Meeker, Oklahoma. AES, Inc. purchased two (2) high-volume units of PCT Corp.’s equipment and is building out has executed a collaborative agreement with Advanced a 2,500 s.f. production facility as it develops its oil & gas and Cannabis applications December 2019.
https://www.para-con.com/images/docs/PCTL12-16-19.pdf
PCT LTD (OTC Pink: PCTL) ("PCTL"), as the result of its wholly owned operating company’s (PCT Corp.’s) growth, is pleased to announce a new distribution partner in Puerto Rico in addition to other ongoing expansion efforts.ABC Medical of San Juan, Puerto Rico (www.abcmedicalpr.com) has signed on to be a distributor and sub-registrant for PCT Corp. in Puerto Rico. Through a sub-registration licensing agreement, which includes royalty revenues to PCT Corp., ABC Medical will initially receive one large volume Hydrolyte® System for the purpose of producing, bottling, and distributing Hydrolyte® solution to their existing hospital and healthcare clients. The move signals the company’s first distribution agreement in an area outside the continental United States March 13, 2020.
https://www.para-con.com/images/docs/PCTL03-13-20.pdf
PCT LTD Discusses Their Unique Annihilyzer™ Disinfecting System and Impact of The Coronavirus with The Stock Day Podcast
Jolly. Grieco shared that the Company remains undervalued considering the effectiveness of their hypochlorous disinfectant system, which is now entering its ninth hospital. “I think that one of the big problems with any small company is profitability,” said Grieco, “I will go out on a limb and say that we will be profitable in the month of March. We will have a record first quarter,” shared Grieco. “I think this month will set a stage,” he added. “I am more optimistic than I’ve ever been with this company, and I’ve been involved with this kind of technology since 1996,” closed Grieco.
https://www.para-con.com/images/docs/PCTL03-16-20.pdf
PCTLis pleased to announce they have obtained a large pre-paid order from an existing sub-registrant in the Midwestern United States for 10,000 gallons of a specific fluid solution, with regular, recurring orders expected to follow in March 2020
https://www.para-con.com/images/docs/PCTL03-18-20.pdf
Little River, South Carolina — (March 25, 2020) PCT LTD (OTC Pink: PCTL) ("PCTL") is continuing to expand business operations at a rapid rate while experiencing a dramatic increase in inquiries and orders from new and existing clients. Following up on an earlier release from March 18th; a second 10,000-gallon fluid order has been shipped to an existing customer in the Midwest. Recurring orders to this sub-registrant are expected to follow in the coming weeks.
https://www.para-con.com/images/docs/PCTL03-25-20.pdf
PCTL is pleased to announce that it has received approval for “emerging pathogens” labeling with the US EPA in March 2020. Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cleaning-disinfection.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Fcleaning-disinfection.html for additional information.
https://www.para-con.com/images/docs/PCTL03-27-20.pdf
PCTL is excited to announce they have increased production capacity at their Little River, South Carolina facility. Updating an earlier release (March 25th), the South Carolina facility is now capable of producing up to 10,000 gallons of fluids per day. A marked increase over earlier capabilities. The company is now better positioned to meet the growing demand for its Hypochlorous Acid-based disinfecting fluids.
https://www.para-con.com/images/docs/PCTL04-07-20.pdf
PCTL is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UKbased partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company in April 2020. In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT’s unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT’s technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021.
https://www.para-con.com/images/docs/PCTL04-16-20.pdf
PCT LTD Discusses Its Rapid Growth and Expansion Plans with The Stock Day Podcast in April 2020. The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
https://www.para-con.com/images/docs/PCTL04-21-20.pdf
PCTL is pleased to announce they are continuing their expansion efforts with additional hospital installations and have reached distributor agreements with three new entities in May 2020. Two of the new distributors will operate in the western United States (California and Utah primarily) while the third distributor is based in South Carolina, shoring up the company’sexisting presence in the state. The company is also announcing a new hospital installation. Following up on an earlier release from April 14th, installation in a large NYC area hospital is expected to commence early next week through PCT’s primary healthcare distributor ACE Janitorial Services. Two additional installations are scheduled in NYC hospitals over the following weeks.
https://www.para-con.com/images/docs/PCTL05-08-20.pdf
PCTL is pleased to announce two additional hospital installations scheduled within this month, announces the relationship between PCTL and Florida-based Sapphire Disinfection Solutions, as well as declares the addition of three new distributors in May 2020. PCTL’s newest distributors are setting up operations in Illinois, New Jersey, and in central South Carolina. Two of the newest distributors will also have supplemental product registrations and the third will be a re-sale distributor of PCTL’s Hydrolyte disinfectant into medical facilities, schools and to state and municipal governments.
https://www.otcmarkets.com/stock/PCTL/news/story?e&id=1608744
PCTL's successful launch of the Annihilyzer System 18 months ago leads to a system in 20% of hospitals in New York City.
Why is PCTL stock set to make a major move?
First of all we need to understand the current trading area is based on the market makers just doing their job of creating a market.
PCTL sales have been record breaking sales and revenues for Q1 and expected to have double digit growth in Q2 and beyond. That alone should be favorable to the stock price movement.
What could launch stock price movement on a crazy run is knowledge.
The PCTL story is unknown to the trading public and the general public and for good reasons. It is a “stink pinky”. A lot of people won’t touch an OTC stock. It just went through some serious toxic financing. We had some very good local news stories about a small company from Little River, SC., however we need national news on the impact of HOCI during the Pandemic.
What major companies make and sell HOCI?
BASF SE. (Germany) OTCMKTS $48.80
Arkema S.A. (France) OTCMKTS $82.05
Lonza. (Swiss) OTCMKTS $480.00
Olin Corporation. NYSE $11.32
Nouryon (Private)
Occidental Petroleum Corporation. NYSE $14.67
Kuehne Company (Private)
AGC Chemicals (Private)
Surpass Chemical Company, Inc. Private
Westlake Chemical Corporation NYSE $42.02
When the story gets out about the impact of and the demand for Hypochlorous Acid during the pandemic and if Paradigm Convergence Technologies Corporation catches some press in the process then the possibility of an epic run may occur.
Why?
When people start to research HOCI and find out who the major players are they may want a piece of the action. Now some of the players listed are private so no action there. Many of the other ones although they make HOCI it is not necessary for disinfection in hospitals or similar businesses. Some will deliver 2500 gallons from a tank truck. Some are big into providing services to farms, diary, pool supplies distributors and water treatment plants.
If by happenstance some of these interested parties stubble across PCTL and take a close look they may take a dip and join the party.
PCTL went from the ashes of toxic financing to a company on a cash flow basis to cover the burn-rate in a six month period.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
THe fact that HOCI is selling like hotcakes and demand has been outstripping supply should be national news.
PCTL gave up big DOLLARS for the technology.
During my time in the Air Force, one of my commanders use to say if it isn't written down it didn't happen.
We are good!!!
Interest...Timely.... Accurate....
FACTS not fiction
Lawsuit:
Why plaintiffs in US patent cases who understand the odds of victory are almost always best off settling?
The vast majority of patent lawsuits settle before trial—95% to 97% of them.
From the 2016 10K:
Paradigm senior research and development personnel have worked for over a year with another company, Annihilare Medical Systems, Inc. (AMS) to perfect a specific model of Paradigm’s portable generation system to be deployed as a component in AMS’s state-of-the-art integrated product dispensing, tracking and management systems for applications in the institutional facilities market. This integrated technologies solution, branded as the Annihilyzer®, has been designed most particularly for hospitals, large long-term care, assisted living and nursing home facilities. In various configurations in can be deployed in other health care facilities including urgent care centers, medical, dental and veterinary offices. It is adaptable to deployment in schools, prisons, hotels and many other facilities. A complete and custom turn-key cleaning, disinfection and sterilization program solution can be provided to each facility.
At the physical core of the Annihilyzer® solution is Paradigm’s on-site generation equipment. The Catholyte product generated in the Annihilyzer® is branded by AMS as Catholyte. It is a non-toxic mild detergent and degreaser that is easily applied using mop buckets, sprayers and floor cleaning machines for basic janitorial cleaning purposes.
Paradigm’s generation equipment is housed in the Annihilyzer® kiosk which also contains a managed disbursement and bottling system which tracks inventory production, containerization and use. Spray bottles and other containers are labeled when filled or refilled with product identification and date of production using printed labels and radio-frequency identification (“RFID”) tags. Reading these labels and tags before use assures that the correct and “fresh” product is always being used. Each room is also given an RFID tag. By reading the RFID room tags with a mobile app in a smartphone, the system tracks what is cleaned and disinfected, when, with what product, and by whom. The kiosk is Wi-Fi connected to smartphones so it can receive and store all of the data collected. The data can be used to generate a complete record of all cleaning, disinfecting and sanitizing activity, including personnel time and task data – a cost saving convenience to management.
From the 2016 10K:
On April 6, 2017, Paradigm, acquired the complete intellectual property, including know-how, trade secrets and patent rights to the hardware, firmware and software comprising the product inventory generation, disbursement, containerization, tracking and reporting system, trademarked as the Annihilyzer® System. The Annihilyzer® System is designed to be employed on-site in healthcare facilities. The company already owns IP rights in the generation system employed in this integrated technology system.
Paradigm has developed proprietary know-how related to the reactor cells and generation systems that generate our Hydrolyte® and Catholyte products. Paradigm continues, through its research and development program, to perfect the production innovation, know-how, trade secrets and patentable innovations incorporated into the improved production, inventory management and reporting systems. Current focus is on customizing system and equipment design to suite the production parameters and conditions in various specific venues and applications, e.g., agricultural field setting vs. packing house or oil and gas field.
Paradigm, pursuant to an agreement with Annihilyzer, Inc., an amendment to which agreement is currently in negotiation with the management of Annihilyzer, Inc., intends to acquire the complete intellectual property, including know-how, trade secrets and patent rights to the hardware, firmware and software comprising the product inventory generation, disbursement, containerization, tracking and reporting system, trademarked as the Annihilyzer® System. The Annihilyzer® System is designed to be employed on-site large facilities. The company already owns IP rights in the generation system employed in this integrated technology system. If successfully completed, the acquisition will result in ownership of the components, patent pending software and firmware, developed by Annihilare Medical Systems and held in their affiliate company Annihilyzer, Inc. A definitive agreement is expected to be executed in the second quarter 2017.
https://dd7pmep5szm19.cloudfront.net/2372/0001554795-17-000173.htm
From the 2017 10K:
On April 6, 2017, Paradigm, acquired the complete intellectual property, including know-how, trade secrets and patent rights to the hardware, firmware and software comprising the product inventory generation, disbursement, containerization, tracking and reporting system, trademarked as the Annihilyzer® System. The Annihilyzer® System is designed to be employed on-site in healthcare facilities. The company already owns IP rights in the generation system employed in this integrated technology system.
On April 6, 2017, the Company acquired intangible assets by issuing 2,250,000 shares of common stock at a deemed value of $1.96 per share ($4,405,050) to Annihilyzer Inc. in order to close on the amended agreement dated April 6, 2017. Pursuant to the terms of the Agreement, as amended, the Company acquired an Annihilyzer patent and all associated intellectual property. In addition, Paradigm granted Annihilyzer Inc, a three-year license and sub-registration under Paradigm’s EPA Product Registration #82341-4. Annihilyzer, Inc. had no activity under this sub-registration agreement as of December 31, 2017.
Hydrolyte® Generation and Equipment Production: Paradigm moved into its new operations, research and development and production facility in Little River, South Carolina on December 15, 2016. The research, development and testing space was suitable and functional as already built. Paradigm’s systems consist of large volume units capable of producing up to 1,000 gallons per day for the Agriculture and Oil & Gas industries. The Annihilyzer systems which are medium to low volume units that are more suitable for the Healthcare market. Testing and assembly of the large volume systems for the Agriculture and Oil & Gas industries is currently being conducted at the new facility. A new design and layout for a final systems assembly area and an expanded testing area was finalized in January 2018 and the internal improvements and equipment installation is expected to be completed and fully operational by July 1, 2018.
Annihilyzer® Systems Assembly: Annihilyzer generator systems are tested and assembled in Little River and the other outsourced components for the Annihilyzer® System are shipped to Werks Manufacturing Inc., Ft. Wayne, Indiana for final assembly in the Annihilyzer® Station cabinet. The Stations and the ESS Carts are manufactured by Werks using RFID patent-pending technology owned by Werks. Werks manufacturing technology enables the near-field communications (NFC) and information systems functions of the Annihilyzer® to work. Station and ESS Cart manufacture and system assembly is performed by Werks on a purchase order basis.
Consulting Agreements – On June 9, 2015, the Company entered into a consulting agreement with one individual to provide various services to the Company. The Company has agreed to pay up to $50,000 in fees to this individual to include all costs associated with the development and procurement of sales including, but not limited to: his time, all testing by the individual and/or other labs at his direction, all travel expenses, sales and marketing brochures and any and all other costs associated with the sales of Anolyte fluids to a specific industry and all related parties. The agreement expired December 31, 2015. On January 1, 2016, the Company amended the previous agreement and extended it for six months through June 30, 2016. The Company agreed to pay the individual an additional $16,500 in consulting fees and expenses. On July 1, 2016, the Company extended the previously amended agreement through December 31, 2016 and agreed to pay an additional $24,000 in consulting fees plus expenses. The Company continued to use the services of this consultant, on a month-to-month basis for $3,000 per month, terminating the use of those on December 31, 2017.
On September 1, 2017, the Company entered into a five-year employment agreement with Marion E. Paris, Jr. to be the Vice President for Business Development and Director of Intellectual Properties for Paradigm. Under the terms of the employment agreement, Mr. Paris is to be paid an annual base salary of $90,000 and other benefits, including four weeks paid vacation. In addition, the Company agreed to pay Mr. Paris a signing bonus of $40,000.
From the 2018 10K:
On April 6, 2017, Paradigm, acquired the complete intellectual property, including know-how, trade secrets and patent rights to the hardware, firmware and software comprising the product inventory generation, disbursement, containerization, tracking and reporting system, trademarked as the Annihilyzer® System. The Annihilyzer® System is designed to be employed on-site in healthcare facilities. The company already owns IP rights in the generation system employed in this integrated technology system.
On April 6, 2017, the Company acquired intangible assets by issuing 2,250,000 shares of common stock at a deemed value of $1.96 per share ($4,405,050) to Annihilyzer Inc. in order to close on the amended agreement dated April 6, 2017. Pursuant to the terms of the Agreement, as amended, the Company acquired an Annihilyzer patent and all associated intellectual property. In addition, Paradigm granted Annihilyzer Inc, a three-year license and sub-registration under Paradigm’s EPA Product Registration #82341-4. Annihilyzer, Inc. had no activity under this sub-registration agreement as of December 31, 2017.
On September 1, 2017, the Company entered into a five-year employment agreement with Marion E. Paris, Jr. to be the Vice President for Business Development and Director of Intellectual Properties for Paradigm. Under the terms of the employment agreement, Mr. Paris is to be paid an annual base salary of $90,000 and other benefits, including four weeks paid vacation. In addition, the Company agreed to pay Mr. Paris a signing bonus of $40,000.
From 2019 3rd 10Q:
On August 8, 2019, we received notice from Annihilare, Inc. that certain intellectual properties developed jointly between us and Annihilare are to be discontinued from use by us and our customers. We dispute the claims from Annihilare that the intellectual properties are exclusively Annihilare’s and are in discussions with Annihilare on this point. We have engaged counsel to assist us with this dispute and are evaluating potential litigation on this matter. However, as of the date of this filing no litigation has been initiated.
On July 30, 2019 the Company accepted a settlement proposal from Annihilare, Inc. (a sub-registrant of the Company’s US EPA Registration No. 92108-1) and its affiliated company, Prime ITS (a prior owner of Annihilyzer Inc, which transferred previously noted intangible IT assets to PCT LTD for 2,250,000 shares of the Company’s common stock in November of 2016). The settlement agreement included credit to the Company by Prime ITS in the gross amount of $23,209 on the Company’s payable to Prime ITS for a combination of a portion of Marty Paris’ salary, a resignation from Marty Paris effective July 31, 2019, and equal valued amount of PCT’s inventory, for net credit to PCT in the amount of $13,939, which was received by the Company on July 31, 2019. The transaction was completed on August 1, 2019.
On August 8, 2019 the Company received notice from PRIME ITS that certain technology services utilized by the Company shall cease to be provided, effective September 8, 2019.
On August 8, 2019 the Company received notice from Annihilare, Inc. that certain intellectual properties developed jointly between the Company and Annihilare are to be discontinued from use by the Company and our customers. We dispute the claims from Annihilare that the intellectual properties are exclusively Annihilare’s and are in discussions with Annihilare on this point.
The Covid-19 Pandemic has changed the thought process of the healthcare and other industries.
Why?
The demand for Infection Control Systems is at an all time HIGH!!!
By the Numbers
271,000 Infection Controls Systems sold yearly!!!
Bids are being requested in the thousands!!!
Growth Rates Through The ROOF 400%...600%...2000%!!!
The need for Infection Control Systems because of the pandemic is record breaking.
https://www.forbes.com/sites/richblake1/2020/04/17/in-covid-19-fight-robots-report-for-disinfection-duty/
What products could have assisted the most in helping and organization to deal with pandemic?
The Annihilyzer is on a lot of organizations lists.
Why?
The Annihilyzer is the best on-site and on-demand solution that is on the market.
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
Will they purchase one?
Time will tell.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
THe fact that HOCI is selling like hotcakes and demand has been outstripping supply should be national news.
The information that will be reflective on the 10k is mostly already known from what was reported on the last quarterly dated 4/13/2020 minus companies operations for the 4th quarter. The 2020 1st quarter report should show the company transitioning as a company on a cash flow basis to cover the burn-rate. The 2nd quarter report should show significant cash flow and an explosive growth not only for fluid sales but Annihilyzers systems as well. If all what PCTL management have been reporting in recents months is true and I don’t doubt them, then the company is in a great position to grow, become financially stable and prepare themselves to move to another exchange.
The day to day stock price is just the market makers doing their job and the stock price will move up and down based on the results (fundamentals) of the company. When the results are fully realized in the future reports especially starting with the 2nd quarter report then it will be reflected in the stock price. Also Press releases, podcasts, and other media outlets may influence the stock price movement.
Why is PCTL stock set to make a major move?
First of all we need to understand the current trading area is based on the market makers just doing their job of creating a market.
PCTL sales have been record breaking sales and revenues for Q1 and expected to have double digit growth in Q2 and beyond. That alone should be favorable to the stock price movement.
What could launch stock price movement on a crazy run is knowledge.
The PCTL story is unknown to the trading public and the general public and for good reasons. It is a “stink pinky”. A lot of people won’t touch an OTC stock. It just went through some serious toxic financing. We had some very good local news stories about a small company from Little River, SC., however we need national news on the impact of HOCI during the Pandemic.
What major companies make and sell HOCI?
BASF SE. (Germany) OTCMKTS $48.80
Arkema S.A. (France) OTCMKTS $82.05
Lonza. (Swiss) OTCMKTS $480.00
Olin Corporation. NYSE $11.32
Nouryon (Private)
Occidental Petroleum Corporation. NYSE $14.67
Kuehne Company (Private)
AGC Chemicals (Private)
Surpass Chemical Company, Inc. Private
Westlake Chemical Corporation NYSE $42.02
When the story gets out about the impact of and the demand for Hypochlorous Acid during the pandemic and if Paradigm Convergence Technologies Corporation catches some press in the process then the possibility of an epic run may occur.
Why?
When people start to research HOCI and find out who the major players are they may want a piece of the action. Now some of the players listed are private so no action there. Many of the other ones although they make HOCI it is not necessary for disinfection in hospitals or similar businesses. Some will deliver 2500 gallons from a tank truck. Some are big into providing services to farms, diary, pool supplies distributors and water treatment plants.
If by happenstance some of these interested parties stubble across PCTL and take a close look they may take a dip and join the party.
PCTL went from the ashes of toxic financing to a company on a cash flow basis to cover the burn-rate in a six month period.
Due to increased attention as a result of the ongoing coronavirus pandemic, PCTL has been on an accelerated pace towards profitability and is preparing for double-digit growth into Q2 and beyond.
“Growth has been tremendous,” says CFO Marion Sofield, adding that the company is expecting to report record sales and revenues in Q1 2020.
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
THe fact that HOCI is selling like hotcakes and demand has been outstripping supply should be national news.
PCTL is in a great position to disrupt the market share of contracts for Infection Control Systems with Healthcare and other industries.
Why did they focus on Healthcare first?
Hospital Disinfectant Products Market to Expand at Growth Rate of ~ 5.3% CAGR from 2018 to 2026 to Reach US$ 17.1 Billion through 2026:
https://www.prnewswire.com/news-releases/hospital-disinfectant-products-market-to-expand-at-growth-rate-of--5-3-cagr-from-2018-to-2026-to-reach-us-17-1-bn-through-2026-transparency-market-research-300999388.html
PCTL has the best solution to a multi-billion dollar problem.
Introducing the Most Technologically Advanced Disinfection System Ever Created to Eliminate Hospital Associated Infections (HAIs) using Patented RFID Technology for Tracking and Disinfecting Protocols.
Annihilyzer: A New Disruptive Technology in the World of Hospital Disinfection
Why is the Annihilyzer Infection Control System one of the best and most versatile in the world ?
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
What can the Annihilyzer do?
Save time and money by generating disinfectant and all-purpose cleaner on-site, on-demand
Eliminate the toughest bacteria, viruses, and fungi, including C. diff, C. auris, MRSA, VRE, blood-borne pathogens, and more.
Create 'industry best' protocols and 'push' them out to your cleaning staff in real-time with the Annihilist dashboard and mobile app
Generate reports that show when the areas were cleaned, who cleaned them, and what was done
Increase staff efficiency and effectiveness with process tracking, training, and accountability
How does the Annihilyzer save companies money?
Costs associated with purchasing and managing chemicals – eliminated
Freight charges for chemical deliveries – eliminated
Chemical container disposal or recycling costs – eliminated
Personal protection gear for cleaning – eliminated
Wastewater disposal costs and related fines for non-compliance – eliminated
Workers comp claims due to chemical burns and fume inhalation – eliminated
Happier, healthier and more productive workers
Same or better cleaning power than traditional hazardous chemicals for less
Eliminates costs associated with ordering, inventorying and disposing of chemicals and containers
Versatile
Grieco added: “All of our hospital customers using our infection control system and disinfectant are utilising the systems as a front-line defence throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors.”
What other Infection Control System can do that?
What other system can provide a disinfectant and cleaner?
Results
Why would a hospital sign a 5-year agreement with PCTL when they could have signed a 2 or 3 year agreement?
I'll tell you why - RESULTS RESULTS RESULTS
SUNY Downstate Medical Center chose to renew their contract with the Company for an additional five years after utilizing the system for one year.
What are the chances at some point in the future when the other SUNY hospitals (Syracuse and Stony Brook) Infection Control Contracts expire that they sign with PCTL?
Why has every hospital that went through the 60 day trial period decided to do a multi-year contract? I'll tell you why - RESULTS RESULTS RESULTS
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
Most Technologically Advanced Disinfection System Ever Created
Annihilyzer the future for Healthcare and other Industries
During the Coronavirus Pandemic a Hospital with the Annihilyzer in place was in a better position than a hospital without it. Many hospitals will be asking themselves what could we have done differently? If they know about the Annihilyzer, having one will certainly be one of their answers. This is not the last so they have to put themselves in the best position for future events.
What is a better investment for a whole room Infection Control System:
Annihilyzer versus an UV system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Also the Annihilyzer cost less than half that of one of the best UV system on the market, the Xenex “LightStrike” cost about $125,000,
Annihilyzer versus a Chemical (Hydrogen Peroxide) based system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Chemical based solutions require protective equipment, are more expensive and are harsh on furniture and one company called Hanosil sells their machine for under $10,000 however it costs $20 in product to clean each room.
PCTL's successful launch of the Annihilyzer System 18 months ago leads to a system in 20% of hospitals in New York City.
PCTL management has invested too much, worked many years,overcame insurmountable hurdles to get the Annihilyzer in the marketplace.
I cannot fathom PCTL letting any filing be late without filing the proper paperwork as they did today.
They have viable products they are selling like hotcakes and one of which (Infection Control Systems) their industry peers are saying they can't keep up with demand.
My gut tells me PCTL is up to something that is very beneficial to the company.
It could be a Deep Pocket Investor.
It could be a merger.
It could be a buyout.
The ball is definitely in PCTL court and how they handle it hopefully will be masterful.
What is intriguing is the cash flow and the need to deliver at least 25 systems a month starting in July which is about 35 days away.
The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
I think they are going to need some serious cash to build at minimum 25 systems a month on a recurring basis.
I think people truly understands what a viable position PCTL and similar companies are in with the arrival of the Pandemic and the tools these companies have to combat it.
FACTS not fiction
PCTL emerging from toxic financing to profitabilty.
The story of PCTL is about a little company trying to develop and introduce state of the art technology across different industries including healthcare, oil and gas, food services and agriculture. To truly see the evolution of PCTL one should follow the numbers and the place to start is the FINANCIALS. What does one see?
PCTL shares increased year to year with an enormous bump up in 2019 due to toxic financing. The company was selling shares to support operations.
PCTL revenues increased year to year with the biggest bump up in 2019. Please note the revenues for 2019 are just through the 3rd quarter as the 2019 10K has not been filed yet.
What does this all mean?
PCTL is a growing company and although it went through some toxic financing they were fortunate to increase sales due to an unprecedented demand for HOCI that put them in a position to cover their burn rate. Also 2019 is the year where PCTL had the most system installs that will most likely increase exponentially in 2020.
As far as the stock price goes once all the fundamentals of the PCTL hit the presses via financials in the upcoming quarters it will be reflected in the stock price.
The story of PCTL is changing daily. FACTS not fiction.
Below are some excerpts from recent filings, followed by some excerpts from press releases. People will try and oppose what is FACT with their fiction which is just not possible.
From the 2016 10K dated 4/14/2017
The number of shares outstanding of the registrant’s common stock as of April 14, 2017 was 37,542,572.
Revenues increased to $113,387 for the year ended December 31, 2016 compared to $141 for the year ended December 31, 2015. The revenue increases for 2016 were due to the increased volume of fluids sold and the sale of a piece of fluid producing equipment.
Research and development expenses increased to $147,917 for the 2016 year compared to $29,871 for the 2015 year. Research and development expenses increased for 2016 due to field testing required for EPA certification.
From the 2017 10K dated 4/17/2018
We had 204 stockholders of record as of April 17, 2018 and 43,409,238 shares outstanding. We have not declared dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future.
Revenues increased to $123,105 for the year ended December 31, 2017 compared to $113,387 for the year ended December 31, 2016. The revenue increases for 2017 were due to the increased volume of fluids sold, the sale of a piece of fluid producing equipment, licensing revenue from EPA sub registration, and placing equipment under the Company’s 2-year Systems Service Agreement (“lease”) in December, 2017.
Research and development expenses increased to $315,385 for the 2017 year compared to $147,917 for the 2016 year. Research and development expenses increased for 2017 due to testing of the application of the Hydrolyte® technology in the oil and gas industry; as a biocide in institutional facilities, such as, hospitals, jails and medical facilities; and in agriculture and food processing.
From the 2018 10K dated 4/15/2019:
The number of shares of the Registrant’s common stock outstanding as of April 12, 2019 was 51,643,048.
Revenues increased to $266,122 for the year ended December 31, 2018 compared to $123,105 for the year ended December 31, 2017. The revenue increases for 2018 were due to the increased volume of fluids sold, the sale of a piece of fluid producing equipment, licensing revenue from EPA sub registration, and placing equipment under the Company’s 2-year Systems Service Agreements (“leases”).
From the 2019 3rd 10Q
The number of shares outstanding of the registrant’s common stock as of April 10, 2020 was 527,813,393 which does not include 427,186,607 shares of common stock reserved against default/conversion of convertible debt.
Revenues increased to $534,852 for the nine months ended September 30, 2019 compared to $153,337 for the nine months ended September 30, 2018. The revenue increase for the period was due to the increased volume of fluids sold, the sale of a duplicate US EPA Registration, licensing revenue from EPA sub registrations, equipment sales and the additional revenue from recurring leased-equipment income.
PCTL emerging from toxic financing to profitabilty.
Paradigm Convergence Technologies Corp (PCT) is a technology licensing company specializing in environmentally safe solutions for global sustainability. The company provides innovative products and technologies for eliminating contamination from water supplies, industrial fluids, hard surfaces, food processing equipment and medical devices.
PCTL launched its flagship product, Annihilyzer® Infection Control System that is designed to help alleviate the growing problems of Hospital Acquired in May 2018.
https://www.para-con.com/images/docs/PCTL5-16-18.pdf
PCTL successfully installed the PCT Annihilyzer® Infection Control System at Johnston UNC Health Care Hospital, in Smithfield, North Carolina in May 2018.
https://www.para-con.com/images/docs/PCTL5-18-18.pdf
PCTL provided with sufficient independent laboratory AOAC efficacy testing data to support PCT claims that our Hydrolyte® product is effective in killing a broad range of microbial pathogens, including C-Diff, TB, HCV, HIV-1, CRE, VRE and MRSA, as well as other bacteria and viruses, qualifying Hydrolyte® as a hospital-level disinfectant in May 2018.
https://www.para-con.com/images/docs/PCTL5-22-18.pdf
PCTL is increasing production capacity in response to expected demand for its Annihilyzer® Infection Control Systems and Large Volume Systems in May 2018. Current sustainable single shift capacity of the facility is 20 to 25 units per month, which can be increased to 40 to 50 units per month with additional production personnel and shifts.
https://www.para-con.com/images/docs/PCTL5-29-18.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions for global sustainability announced today it has entered into a license and distribution agreement with a long established agricultural chemical company. The one-year exclusive agreement, subject to renewal, provides for license fees and monthly royalty and equipment leasing payments in September 2018.
https://www.para-con.com/images/docs/PCTL-9-26-18.pdf
PCTL announced today it has entered into a Master Services Agreement with a New Yorkbased hospital supply and services company for the installation of two Annihilyzer® Infection Control Systems to prevent hospital-acquired infections (HAI’s) in hospitals in its market area in October 2018.
https://www.para-con.com/images/docs/PCTL10-25-18.pdf
PCTL announced today that, with its New York-based representative, it has entered into a contractual agreement for the installation and operation of two Annihilyzer® Infection Control Systems in a major Brooklyn hospital in November 2018.
https://www.para-con.com/images/docs/PCTL11-01-18.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions for infection control, secured a three-year Master Service Agreement and recently installed its Annihilyzer® Infection Control System at Carson Tahoe Regional Medical Center in Carson City, NV.
https://www.para-con.com/images/docs/PCTL-01-10-19.pdf
PCTL, a leader in environmentally safe, nontoxic, antimicrobial solutions for infection control, announced today it has entered into a Manufacturer’s Representative Agreement with DTS of Cleveland, OH (DTS), for the sale of Annihilyzer® Infection Control Systems in Ohio, West Virginia, Western Pennsylvania, Michigan, Indiana and Kentucky.
https://www.para-con.com/images/docs/PCTL-02.07.19.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions announced today it has received a repeat order for two large volume Hydrolyte® Systems from one of its existing food processing customers. The referenced food processing customer’s plant currently has two systems at one facility and purchased another large volume system from PCT as a result of their 2018 plant expansion.
https://www.para-con.com/images/docs/PCTL-02.12.19.pdf
PCTL, a leader in environmentally safe, non-toxic, antimicrobial solutions announced today it has sold and is currently installing a large volume C-104 Hydrolyte® Systems to an existing customer, H2S Safe Treat, Inc. of Ada, OK (H2S).
https://www.para-con.com/images/docs/PCTL-02.25.19.pdf
PCTL, announced today that ACE Janitorial Supply Company (“ACE”), PCT Corp.’s distributor for the New York hospital and healthcare market, received a new purchase order for Morgan Stanley Presbyterian Children’s Hospital to continue using PCT Corp.’s patented Annihilyzer® Infection Control System following a successful 60-day trial within the facility.
https://www.para-con.com/images/docs/PCTL5-06-19.pdf
PCTL, announces another successful phase one installation of PCT Corp.’s Annihilyzer® Infection Control System in coordination with its primary healthcare distributor, ACE Janitorial Services. PCT Corp.installed the premier cabinet model of its Annihilyzer® Infection Control System this week at Mount Sinai South Nassau Medical Center located in Oceanside, NY.
https://www.para-con.com/images/docs/PCTL10-07-19.pdf
PCTL, a Little River, South Carolina company and the designer of the Annihilyzer® Infection Control System, a world class whole room cleaning and disinfecting system for hospitals and health care facilities, is pleased to announce that it has shipped the first overseas Annihilyzer® Infection Control System to its partner company, PCT Europe Ltd., in the United Kingdom.
https://www.para-con.com/images/docs/PCTL10-22-19.pdf
Most recently, PCTL Environmental Solutions, Inc. (“AES, Inc.”) of Meeker, Oklahoma. AES, Inc. purchased two (2) high-volume units of PCT Corp.’s equipment and is building out has executed a collaborative agreement with Advanced a 2,500 s.f. production facility as it develops its oil & gas and Cannabis applications December 2019.
https://www.para-con.com/images/docs/PCTL12-16-19.pdf
PCT LTD (OTC Pink: PCTL) ("PCTL"), as the result of its wholly owned operating company’s (PCT Corp.’s) growth, is pleased to announce a new distribution partner in Puerto Rico in addition to other ongoing expansion efforts.ABC Medical of San Juan, Puerto Rico (www.abcmedicalpr.com) has signed on to be a distributor and sub-registrant for PCT Corp. in Puerto Rico. Through a sub-registration licensing agreement, which includes royalty revenues to PCT Corp., ABC Medical will initially receive one large volume Hydrolyte® System for the purpose of producing, bottling, and distributing Hydrolyte® solution to their existing hospital and healthcare clients. The move signals the company’s first distribution agreement in an area outside the continental United States March 13, 2020.
https://www.para-con.com/images/docs/PCTL03-13-20.pdf
PCT LTD Discusses Their Unique Annihilyzer™ Disinfecting System and Impact of The Coronavirus with The Stock Day Podcast
Jolly. Grieco shared that the Company remains undervalued considering the effectiveness of their hypochlorous disinfectant system, which is now entering its ninth hospital. “I think that one of the big problems with any small company is profitability,” said Grieco, “I will go out on a limb and say that we will be profitable in the month of March. We will have a record first quarter,” shared Grieco. “I think this month will set a stage,” he added. “I am more optimistic than I’ve ever been with this company, and I’ve been involved with this kind of technology since 1996,”
https://www.para-con.com/images/docs/PCTL03-16-20.pdf
PCTLis pleased to announce they have obtained a large pre-paid order from an existing sub-registrant in the Midwestern United States for 10,000 gallons of a specific fluid solution, with regular, recurring orders expected to follow in March 2020
https://www.para-con.com/images/docs/PCTL03-18-20.pdf
Little River, South Carolina — (March 25, 2020) PCT LTD (OTC Pink: PCTL) ("PCTL") is continuing to expand business operations at a rapid rate while experiencing a dramatic increase in inquiries and orders from new and existing clients. Following up on an earlier release from March 18th; a second 10,000-gallon fluid order has been shipped to an existing customer in the Midwest. Recurring orders to this sub-registrant are expected to follow in the coming weeks.
https://www.para-con.com/images/docs/PCTL03-25-20.pdf
PCTL is pleased to announce that it has received approval for “emerging pathogens” labeling with the US EPA in March 2020. Hydrolyte® has demonstrated effectiveness against viruses similar to SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. Refer to the CDC website at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cleaning-disinfection.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Fcleaning-disinfection.html for additional information.
https://www.para-con.com/images/docs/PCTL03-27-20.pdf
PCTL is excited to announce they have increased production capacity at their Little River, South Carolina facility. Updating an earlier release (March 25th), the South Carolina facility is now capable of producing up to 10,000 gallons of fluids per day. A marked increase over earlier capabilities. The company is now better positioned to meet the growing demand for its Hypochlorous Acid-based disinfecting fluids.
https://www.para-con.com/images/docs/PCTL04-07-20.pdf
PCTL is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UKbased partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company in April 2020. In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT’s unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT’s technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021.
https://www.para-con.com/images/docs/PCTL04-16-20.pdf
PCT LTD Discusses Its Rapid Growth and Expansion Plans with The Stock Day Podcast in April 2020. The conversation then turned to dilution and outstanding shares. Grieco noted that dilution occurred prior to January 2020, but shared that any shares that are currently being issued are meant for growth. “We are in a position as a company on a cash flow basis to cover the burn-rate,” said Grieco. “So, we finally have free available cash flow,” he added. “We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
https://www.para-con.com/images/docs/PCTL04-21-20.pdf
PCTL is pleased to announce they are continuing their expansion efforts with additional hospital installations and have reached distributor agreements with three new entities in May 2020. Two of the new distributors will operate in the western United States (California and Utah primarily) while the third distributor is based in South Carolina, shoring up the company’sexisting presence in the state. The company is also announcing a new hospital installation. Following up on an earlier release from April 14th, installation in a large NYC area hospital is expected to commence early next week through PCT’s primary healthcare distributor ACE Janitorial Services. Two additional installations are scheduled in NYC hospitals over the following weeks.
https://www.para-con.com/images/docs/PCTL05-08-20.pdf
PCTL is pleased to announce two additional hospital installations scheduled within this month, announces the relationship between PCTL and Florida-based Sapphire Disinfection Solutions, as well as declares the addition of three new distributors in May 2020. PCTL’s newest distributors are setting up operations in Illinois, New Jersey, and in central South Carolina. Two of the newest distributors will also have supplemental product registrations and the third will be a re-sale distributor of PCTL’s Hydrolyte disinfectant into medical facilities, schools and to state and municipal governments.
https://www.otcmarkets.com
PCTL from doom and gloom to BOOM!!!
HUGH POTENTIAL
How could a company go from needing an “angel funder” with 3.5-5 million dollars to invest to record sales for the quarter and profitable for the month of March 2020 all in a week’s time?
I’ll tell you how HOCI!
The question now is do they still need the 3.5-5 million dollars?
Do they have that 3.5-5 million dollars lined up due to their sudden windfall?
Don’t know
Thoughts
It has a record breaking Q1 for sales and revenues.
PCTL is a growing company and although it went through some toxic financing, they were fortunate enough to increase sales due to an unprecedented demand for HOCI that put them in a position to cover their burn rate. Also 2019 is the year where PCTL had the most system installs that will most likely increase exponentially in 2020.
PCTL revenues increased year to year with the biggest bump up in 2019. Please note the revenues for 2019 are just through the 3rd quarter as the 2019 10K has not been filed yet.
2015 $141
2016 $113,387
2017 123,105
2018 $266,122
2019 $534,852 thru 9 months
2020 $$$$$$$$$$$$$$
2021 $$$$$$$$$$$$$$$$$$$$$$
2022 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
From the March 9, 2020 CEOCFO Magazine interview:
CEOCFO: Are you funded now? Are you seeking partnership, investments or funding as you move forward?
Mr. Grieco: Yes. Obviously, for a small company, that has been our greatest, most stubborn obstacle! First of all, the length of time that it takes to get into hospitals, and second of all, the length of time; even once you make your first presentation, the average time is about six months before you get them to agree to a Phase I Installation! Those things are very costly for us to provide. We are sending in our own Infection Preventionist, former Hospital EVS Administrator and our Technical Engineer to discuss our system, the fluid side itself and on how all the machines operate; that’s expensive. Therefore, yes! We are certainly looking for funding now; I guess the correct term would be an angel funder, from this point. Someone who understands what we do, sees its impact on the healthcare system of this country, sees its impact on a company that can deliver a solution to that and is willing to commit three and one half to five million dollars to that process.
From the PR dated March 13, 2020:
As a result of increased demand, an existing customer, BioBlasting LLC of Egg Harbor Township, New Jersey (www.bioblasting.com) has also purchased two of PCT Corp.’s largevolume Hydrolyte® generators.
"Our company has been growing exponentially over the past 2 years as our clients have discovered the benefits of our fluid solutions, which offer a high level of safety for both staff members and the general public," says BioBlasting CEO, Arthur Handson. "In light of the recent outbreak, our team has been working around the clock to ensure our products are accessible to all people and industries, particularly schools. Our goal is to minimize the effects of infectious disease outbreak by implementing proper preventive measures as well as assisting with eradication procedures as needed."
"We’ve had a great relationship with BioBlasting for over two years," says PCT LTD CEO, Gary Grieco. "As an existing sub-registrant, they have seen firsthand the safety and efficacy of our product. We’re happy to take this next step with them and excited to support them in their growth and efforts to serve their customers and communities."
As a result of heightened demand, PCT Corp. is expediting plans to increase its distribution networks. "With everything going on in the world today, our demand has increased by leaps and bounds" says PCT Corp. President, Bill Prince. "Adding key distributors to our network will allow us to strengthen sales channels and accelerate revenue growth while at the same time providing a much-needed product and service during these critical times. We will strategically add additional distributors and "partners," both In the United States and abroad. This will allow us to keep up with the strong need for our products."
From the March 16, 2020 Stock Day Podcast:
“How do you view the short to medium term of your company’s sales going forward?”, asked Jolly. Grieco shared that the Company remains undervalued considering the effectiveness of their hypochlorous disinfectant system, which is now entering its ninth hospital. “I think that one of the big problems with any small company is profitability,” said Grieco, “I will go out on a limb and say that we will be profitable in the month of March. We will have a record first quarter,” shared Grieco. “I think this month will set a stage,” he added.
“I am more optimistic than I’ve ever been with this company, and I’ve been involved with this kind of technology since 1996,” closed Grieco.
Opportunity fell on their doorstep and they took full advantage of it.
PCTL is a stock with the right product at the right time.
PCTL to the Moon and Beyond!!!
Gary did not fail!!!
In any start-up business there will be failures. You either quit or you press on.
PCTL’s financial situation was dire and they did what they had to do, toxic financing.
Does that constitute failure? No
Actually years and years before the Pandemic the company's share structure was small and its stock price was as high as $2.50.
If anything he got lucky.
Bringing PCTL’s flagship product, The Annihililyzer, to the market was not easy nor cheap.
“It is just a long arduous problem getting into the hospitals because of the layers of people that you have to go through,” said Grieco. “We have found that from the initial discussion with a hospital, it takes about six months before we get a system in there,” he explained. Grieco then shared that the Company has installed multiple systems in New York hospitals and are in discussions with additional New York facilities.
PCTL's plan was to increase market share in the healthcare and other industries.
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
That is success not failure!!!!!!!!!!!!!!!!
From the April 21, 2020 Stock Day Podcast:
“We have to expand very rapidly. We see a need, starting in July, to start delivering at least 25 systems a month,” said Grieco.
SUCCESS SUCCESS SUCCESS
Delivering to whom. Not the UK because they were still evaluating the Annihilyzer.
They either have a contract or a crystal ball.
HUGH simply HUGH
Timely and accurate....
FACTS not fiction
Is PCTL deceiving shareholders with false information on HOCI sales:
In the economic and political arenas, deception may appear in a wide variety of forms. Indeed, cynical observers might argue that a synonym for economic disinformation is “advertising.” In any case, examining the use of deception in marketing helps illustrate the difference between “fabrication and manipulation.” If false information is created and presented as true, this is fabrication. It is fabricated for the purpose of disinformation and is simply not true. Manipulation, on the other hand, is the use of information which is technically true, but is being presented out of context in order to create a false implication. This deception may be achieved by leaving out information or by associating valid information in such a way as to create false correlations. In the advertising world, companies usually avoid making false claims based on “fabricated” information. The laws against false advertising make such behavior problematical. Presenting “true” information “manipulated” to create a false impression, however, is difficult to prosecute. An example of some automobile manufacturers advertised cars with inefficient fuel consumption by noting how the range of their vehicles compared to smaller, more fuel efficient automobiles. They simply neglected to point out that their gas tanks were considerably larger than those in the smaller vehicles.
Well I don’t believe so because of independent reports of unprecedented sales:
In 2018, Pure & Clean’s annual revenue was $350,000. Amid the COVID-19 pandemic, you say sales of your natural disinfectants have surged in the last month. What were March sales?
It was equal to [total] 2019 sales, which were more than double 2018 sales. It’s kind of an interesting feeling in this time of so many people hurting with small businesses and even large businesses. We’re a great solution for what’s going on, for protecting yourself and then also for disinfecting surfaces and areas. Scaling to that is obviously something that you can’t prepare for and we obviously weren’t ready for."
I believe the reference is clearly to the annual revenue of $350,000 because it intentionally included the word total.
The article references natural disinfectants (HOCI being one).
The article talks about scaling.
The article talks about local demand and mentions working with some of the largest hospitals in the country.
It’s from individuals just wanting to get something to protect themselves. A lot of those individuals are people who are working on the front lines of the health care systems in town. A lot of people are in long-term care facilities that are taking care of a high-risk population. Honestly, our business right now, a lot of it is from all over the nation. Large companies reaching out that need to protect their employees. We work with some of the largest hospital systems in the nation.
The article talks about inability to meet demands.
We were supposed to be at the NCAA wrestling championships in March in Minnesota. I was supposed to go from there to Vision Expo East in New York and that was canceled. We were supposed to be at the Olympics this summer with our products. Team USA had already purchased product to be shipped out to Japan for the Olympics. Our sports line has pretty much been shut down, and our medical and consumer side is just crazy. We have to take care of our existing customers, and their medical side that are front line and we’re also working with some new ones, but we definitely can’t meet all the demand. The largest companies out there can’t come close to meeting all their demands. So, obviously a young, family-owned business like ours, we’re doing the best we can.
This article is all about HOCI and $700,000 Pure&Clean sold in March.
Their biggest HOCI item on their website is a 265 gallon tote.
It wouldn’t take too many of those to get to $700,000.
A Clearwater company saw sales for its advanced hypochlorous skin spray skyrocket from 120 bottles a month to 20,000 in March, and it appears COVID-19 may be the reason.
"I started polling my customers to find out, 'Why are you buying it? Why are you buying it?' Because I suspected it was something to do with the virus, but I can't make any claims," said Curativa Bay CEO Bill Maher.
Maher said the feedback he got was that people were attracted by the spray's main ingredient, hypochlorous acid.
Hypochlorous acid is named as the active ingredient in a number of disinfectants on the U.S. Environmental Protection Agency's "List N", which meet criteria for use against the coronavirus.
Here is the deal:
The unprecedented demand for HOCI gave PCTL a freaking financial heart transplant. It literally change the landscape of PCTL financing in a very short period of time.
One must understand though that the HOCI demand was just a situation of PCTL having the right product at the right time.
The end game for PCTL has always been and is its flagship product the Annihilyzer.
During the height the pandemic in NYC I could only imagine some of the conversations going on between hospitals needing supplies. When the talks turn to needing disinfection supplies and a hospital with an Annihilyzer tells another "I got your back" may have created a situation of I gotta get me one of those Annihilyzers.
PCTL is in a great position to disrupt the market share of contracts for Infection Control Systems with Healthcare and other industries.
Why did they focus on Healthcare first?
Hospital Disinfectant Products Market to Expand at Growth Rate of ~ 5.3% CAGR from 2018 to 2026 to Reach US$ 17.1 Billion through 2026:
https://www.prnewswire.com/news-releases/hospital-disinfectant-products-market-to-expand-at-growth-rate-of--5-3-cagr-from-2018-to-2026-to-reach-us-17-1-bn-through-2026-transparency-market-research-300999388.html
PCTL has the best solution to a multi-billion dollar problem.
Introducing the Most Technologically Advanced Disinfection System Ever Created to Eliminate Hospital Associated Infections (HAIs) using Patented RFID Technology for Tracking and Disinfecting Protocols.
Annihilyzer: A New Disruptive Technology in the World of Hospital Disinfection
Why is the Annihilyzer Infection Control System one of the best and most versatile in the world ?
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
What can the Annihilyzer do?
Save time and money by generating disinfectant and all-purpose cleaner on-site, on-demand
Eliminate the toughest bacteria, viruses, and fungi, including C. diff, C. auris, MRSA, VRE, blood-borne pathogens, and more.
Create 'industry best' protocols and 'push' them out to your cleaning staff in real-time with the Annihilist dashboard and mobile app
Generate reports that show when the areas were cleaned, who cleaned them, and what was done
Increase staff efficiency and effectiveness with process tracking, training, and accountability
How does the Annihilyzer save companies money?
Costs associated with purchasing and managing chemicals – eliminated
Freight charges for chemical deliveries – eliminated
Chemical container disposal or recycling costs – eliminated
Personal protection gear for cleaning – eliminated
Wastewater disposal costs and related fines for non-compliance – eliminated
Workers comp claims due to chemical burns and fume inhalation – eliminated
Happier, healthier and more productive workers
Same or better cleaning power than traditional hazardous chemicals for less
Eliminates costs associated with ordering, inventorying and disposing of chemicals and containers
Versatile
Grieco added: “All of our hospital customers using our infection control system and disinfectant are utilising the systems as a front-line defence throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors.”
What other Infection Control System can do that?
What other system can provide a disinfectant and cleaner?
Results
Why would a hospital sign a 5-year agreement with PCTL when they could have signed a 2 or 3 year agreement?
I'll tell you why - RESULTS RESULTS RESULTS
SUNY Downstate Medical Center chose to renew their contract with the Company for an additional five years after utilizing the system for one year.
What are the chances at some point in the future when the other SUNY hospitals (Syracuse and Stony Brook) Infection Control Contracts expire that they sign with PCTL?
Why has every hospital that went through the 60 day trial period decided to do a multi-year contract? I'll tell you why - RESULTS RESULTS RESULTS
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
Most Technologically Advanced Disinfection System Ever Created
Annihilyzer the future for Healthcare and other Industries
During the Coronavirus Pandemic a Hospital with the Annihilyzer in place was in a better position than a hospital without it. Many hospitals will be asking themselves what could we have done differently? If they know about the Annihilyzer, having one will certainly be one of their answers. This is not the last pandemic so they have to put themselves in the best position for future events.
What is a better investment for a whole room Infection Control System:
Annihilyzer versus an UV system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Also the Annihilyzer cost less than half that of one of the best UV system on the market, the Xenex “LightStrike” cost about $125,000,
Annihilyzer versus a Chemical (Hydrogen Peroxide) based system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Chemical based solutions require protective equipment, are more expensive and are harsh on furniture and one company called Hanosil sells their machine for under $10,000 however it costs $20 in product to clean each room.
Yea the Annihilyzer doesn't just disinfect rooms it has solutions to clean the whole hospital.
FACTS not fiction
PCTL is in a great position to disrupt the market share of contracts for Infection Control Systems with Healthcare and other industries.
Why did they focus on Healthcare first?
Hospital Disinfectant Products Market to Expand at Growth Rate of ~ 5.3% CAGR from 2018 to 2026 to Reach US$ 17.1 Billion through 2026:
https://www.prnewswire.com/news-releases/hospital-disinfectant-products-market-to-expand-at-growth-rate-of--5-3-cagr-from-2018-to-2026-to-reach-us-17-1-bn-through-2026-transparency-market-research-300999388.html
PCTL has the best solution to a multi-billion dollar problem.
Introducing the Most Technologically Advanced Disinfection System Ever Created to Eliminate Hospital Associated Infections (HAIs) using Patented RFID Technology for Tracking and Disinfecting Protocols.
Annihilyzer: A New Disruptive Technology in the World of Hospital Disinfection
Why is the Annihilyzer Infection Control System one of the best and most versatile in the world ?
The Annihilyzer System is truly a cost-effective Green Seal Certified end-to-end total facility disinfection and cleaning system. This system generates both a hospital grade disinfectant and a very effective cleaning solution to cover virtually all of your cleaning and disinfection needs. These on-site generators produce stable electrochemically activated solutions, OSG 460D - Hospital Grade Disinfectant that is effective against C. diff, MRSA, and VRE, and an OSG 11-12 All Purpose Cleaner, and downtime for the process is only 15 - 20 minutes with no special preparation or precautions necessary.
The Annihilyzer System doesn't stop there, though. The icing on the cake is our state-of-the-art whole-room and handheld electrostatic sprayers that make quick work of completely disinfecting a room. Our 460D disinfectant can even be used to disinfect floors without leaving a haze or residue. We use a powerful non-synthetic disinfectant along with an automated electrostatic spray cart and/or electrostatic sprayers and patented RFID tracking technology that together are unmatched the industry to ensure proper and complete application.
What can the Annihilyzer do?
Save time and money by generating disinfectant and all-purpose cleaner on-site, on-demand
Eliminate the toughest bacteria, viruses, and fungi, including C. diff, C. auris, MRSA, VRE, blood-borne pathogens, and more.
Create 'industry best' protocols and 'push' them out to your cleaning staff in real-time with the Annihilist dashboard and mobile app
Generate reports that show when the areas were cleaned, who cleaned them, and what was done
Increase staff efficiency and effectiveness with process tracking, training, and accountability
How does the Annihilyzer save companies money?
Costs associated with purchasing and managing chemicals – eliminated
Freight charges for chemical deliveries – eliminated
Chemical container disposal or recycling costs – eliminated
Personal protection gear for cleaning – eliminated
Wastewater disposal costs and related fines for non-compliance – eliminated
Workers comp claims due to chemical burns and fume inhalation – eliminated
Happier, healthier and more productive workers
Same or better cleaning power than traditional hazardous chemicals for less
Eliminates costs associated with ordering, inventorying and disposing of chemicals and containers
Versatile
Grieco added: “All of our hospital customers using our infection control system and disinfectant are utilising the systems as a front-line defence throughout their facilities, including in all public area such as restrooms, lobbies, waiting rooms, elevators, corridors, cafeterias, etc. all throughout the day and night and in the presence of patients, staff and visitors.”
What other Infection Control System can do that?
What other system can provide a disinfectant and cleaner?
Results
Why would a hospital sign a 5-year agreement with PCTL when they could have signed a 2 or 3 year agreement?
I'll tell you why - RESULTS RESULTS RESULTS
SUNY Downstate Medical Center chose to renew their contract with the Company for an additional five years after utilizing the system for one year.
What are the chances at some point in the future when the other SUNY hospitals (Syracuse and Stony Brook) Infection Control Contracts expire that they sign with PCTL?
Why has every hospital that went through the 60 day trial period decided to do a multi-year contract? I'll tell you why - RESULTS RESULTS RESULTS
How many hospitals are in NYC?
There are 62 acute care hospitals in New York City.
How many hospitals in NYC have at least one Annihilyzer System?
PCTL has installed at least 12 systems and gained 19% market share in NYC hospitals in less than 18 months.
Most Technologically Advanced Disinfection System Ever Created
Annihilyzer the future for Healthcare and other Industries
During the Coronavirus Pandemic a Hospital with the Annihilyzer in place was in a better position than a hospital without it. Many hospitals will be asking themselves what could we have done differently? If they know about the Annihilyzer, having one will certainly be one of their answers. This is not the last so they have to put themselves in the best position for future events.
What is a better investment for a whole room Infection Control System:
Annihilyzer versus an UV system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Also the Annihilyzer cost less than half that of one of the best UV system on the market, the Xenex “LightStrike” cost about $125,000,
Annihilyzer versus a Chemical (Hydrogen Peroxide) based system?
They both disinfect effectively however the Annihilyzer provides an additional products, an all purpose cleaner and handheld electrostatic sprayers that can be used in other parts of the hospital in the presence of people because it is “Green Certified”.
Chemical based solutions require protective equipment, are more expensive and are harsh on furniture and one company called Hanosil sells their machine for under $10,000 however it costs $20 in product to clean each room.
Setting the stage for decontamination
https://insurancenewsnet.com/oarticle/setting-the-stage-for-decontamination#.XswavIjYrrc
Although the Annihilyzer is not mention in the article it is a better solution then all that is mention because it does just disinfect rooms, it cleans the whole hospital.
Room disinfection stars in an ensemble cast, not a one-man show
Just like sterile processing professionals know how important it is to clean instruments before sterilization (if it's not clean, it can't be sterile) environmental service teams know how important it is to clean surfaces thoroughly before using their whole-room disinfection equipment, which more and more hospitals are including in their bundled approach to cleaning and disinfecting areas throughout the facility.
Dress rehearsal
"I like to think of room disinfection systems as an insurance policy; it provides that additional assurance that we have done everything we can to protect our patients," said Lorene Campbell, BSN, RN, CIC, Infection Specialist, Valley Children's Hospital, Madera, CA. "But in order for room disinfection systems to achieve the best results, room surfaces must first be thoroughly cleaned. These devices cannot disinfect through dirt. A properly cleaned environment is essential to prevent healthcare-associated infections (HAIs)."
Once that first critical cleaning step is completed, room disinfection machines - using ultraviolet emitters, xenon robots, chemical foggers, misters, atomizers, etc., - provide an extra layer of valuable protection. Research shows all types can make a significant impact on HAI reduction compared to cleaning alone. As for ultraviolet technologies, "The multitude of commercially-available devices makes choosing a device difficult," wrote William A. Rutala, PhD, MPH, coauthor of a 2019 study. "UV devices may vary because of differences in UV wavelength, dose, ability to measure dose and cost. For these reasons, Infection Preventionists should review the peer-reviewed literature and choose for purchase only devices with demonstrated bactericidal capability as assessed by carrier test method and/or ability to disinfect actual rooms."1
The adoption of these machines is catching on ... sort of. According to Healthcare Purchasing News' 2019 infection prevention (IP) survey results, many IP professionals said their facility uses some type of wholeroom disinfection system, but just as many said no, they did not use such equipment. We also heard from a number of respondents who said their organizations were considering implementing a system. Cost and budget restraints are the most likely reasons hospitals are not making the purchase or still on the fence about it, Campbell said, and of course choosing which type of disinfection system is right for your facility is another factor that requires considerable thought and research.
What exactly should one keep in mind when shopping around? "Highest possible kill of all relevant organisms, simplicity, cost effectiveness, leaves no residue, patient and staff safety, speed of completion, and evidence to support claims," is the list of factors that Campbell suggests value analysis teams should be thinking about when reviewing room disinfection products.
As for making the case to leadership about buying one, Campbell recommends submitting a detailed business proposal based on data and a cost analysis. "Data should include compliance to the bundle practices, PPE, hand hygiene, high-touch surface cleaning, EVS cleaning audits, and HAIs," she said. "If compliance is low in these areas, focus should shift to increasing compliance prior to submitting the proposal. If or when compliance is high and HAIs have not been decreasing, provide data to support your proposal. Include the cost of the system and the cost of HAIs. Data helps drive change." And here's the best news: Since most systems offer a trial period, there's no upfront costs or commitments to make which means you can take advantage of the opportunity to show and tell how room disinfection systems can drive down HAI rates and increase patient safety and satisfaction.
As for the many disinfectant products currently available, Healthcare Purchasing News reached out to a variety of different suppliers and asked them to give us their best pitch on what makes their products worth talking about. As expected, all were very passionate and dedicated to providing the best solution and each one also supported claims with research and casestudy examples. Here's some of what they said about the different types of modalities provided.
A mist sets the scene
"HaloMist, when dispensed by a HaloFogger, is EPA-validated to produce a 6-log kill (de-activation) of C. difficile spores in all the nooks and crannies of complex rooms. There can be no approved kill rate higher than 99.9999 percent, so the HDS (Halo Disinfection System) is one of a very small number of systems (one of four) to have that distinction in the U.S.," asserted said David St.Clair, Chairman, CFO, Halosil International, Inc. "All four such systems are hydrogen peroxide-based, with two using an aerosol and two using hydrogen peroxide vapor. Tire EPA requires a 99.9999 percent kill rate against C. diff spores to allow any claim against tliem to be made, tire name for which is "sporicidal." Normally, to be classified as a disinfectant, a kill of ? at least 99.99 percent . r against vegetative bacteria and viruses is required. To be an EPA-registered "sanitizer," a kill rate of 99.9 percent is generally the target.
When our product is initially used as recommended - on operating rooms at night and on isolation rooms upon discharge - the addition to a hospital's average room turn-around time is measured in minutes," St. Clair continued. "Pennsylvania Hospital, for instance, fogs only about 4 percent of their patient discharges, and those each take about two hours or less after the normal 30-minute cleaning. But since it's only 4 percent, that represents 4 percent of 150 minutes, or 6 minutes of the average. If the hospital takes 45 minutes for the other rooms it disinfects by hand, that represents 96 percent of 45 minutes, or 43.2 minutes. Tire average, then, is 43.2 + 6, or 49.2 minutes per room vs. 45 minutes on average for essentially still-infected rooms. And if UV systems take 45-60 minutes or more after normal cleaning to kill any level of C. diff spores, then their number is (4 percent x (30 h-50)) + (96 percent x 45) = 46.4 minutes for rooms still with at least 70,000 times more C. diff spores left "alive" for the next patient (that's the difference between 99.9999 percent and 93 percent kill rates).
"The HDS is a fraction of the capital cost - roughly 1/6th - of the other three EPA-approved systems, and between 1/4th to 1/12th the cost of any UV system known to us," St. Clair said. "The bottom line for the Halo Disinfection System is that it is the most effective and most affordable whole-room disinfection system legally on the U.S. market (there may be illegal - i.e. not EPA-approved - chemical disinfection systems out there that also work, in spite of the significant liability risks they bring with them)."
Next up is Ed Striefsky, Vice President of Sales and Operations at Bioquell: "We have over 15 years' experience and 55 scientific publications supporting the use of our technology in a wide range of settings and with proven outcomes reducing HAIs," he said. "At Bioquell we use high quality 35 percent hydrogen peroxide to deliver a genuinely effective 6-log reduction to all parts of the target area, every time. Each Bioquell cycle can be independently validated by using Geobacillus stearothermophilus biological indicators, so not only is the equipment safe, small, fast, easy to use and regulatory compliant, but you can also be sure that it works. The important part of what you asked is in the wording 'whole room disinfection.' That is what Bioquell Hydrogen Peroxide Vapor technology offers. We are global leaders in providing this type of disinfection for the entire room, not just high touch areas, with the same level of efficacy throughout.
"A Bioquell decontamination cycle, much like any enhanced decontamination technology, will have a variable duration based on several key environmental factors, most notably the size of the room," Striefsky continued. "An average single patient room can be decontaminated in approximately 1.5 to 2 hours depending on conditions, while larger areas may take longer. It is important to note that tinis represents tire complete cycle time, which can be broadly broken down into 3 stages - vaporization, dwell and aeration. At the end of a Bioquell cycle the room can be immediately reoccupied. We utilize powerful catalytic aeration units to rapidly breakdown and remove the vapor following its injection into the room, thus ensuring the fastest possible total cycle time.
"Using a Bioquell system will ensure you only have to run a single cycle each time, with no need to move the system around the room, worry about 'line of sight' limitations or be concerned about the distance between the generator and the surface to be decontaminated. Bioquell's products have been consistently proven to be effective against a wide range of target organisms, including bacteria, viruses and even resistant spores. Studies consistently show that manual cleaning alone will leave a high percentage of surfaces within a room contaminated, often over 50 percent. When combined with several extensive studies that show leading U.S. hospitals were able to reduce nosocomial infection by 39 percent to 60 percent while using Bioquell equipment, it starts to paint a picture of the potentially huge cost savings that can be achieved through successfully implementing Bioquell equipment or our in-house daily decontamination service called the Bioquell Proactive."
Nevoa, Inc., hangs its hat on offering a patented, hospital-grade surface disinfecting system approved for atomizing an EPA-registered solution that contains the active ingredient Hypochlorous Acid (HOCl). "The system is comprised of two components. Nimbus - a machine that deploys ("atomizes") a liquid solution into a hospital room to disinfect all surfaces and equipment, with no line-of-sight issues, and Microburst - an EPA-registered solution whose active ingredient is Hypochlorous Acid (HOCl)," asserted Ernest Cunningham, President, Nevoa, Inc. "Together, the Nimbus + Microburst system eradicates pathogens in patient rooms, lowering a patient's risk of acquiring Healthcare Associated Infections (HAI), reducing hospital costs and improving the patient experience.
"A University of Arizona (U of A) study showed that Nevoa's Nimbus + Microburst protocol resulted in average microbial log reduction of 4.68; and when combined with a modified manual cleaning protocol, the Nimbus + Microburst protocol using Hypochlorous Acid (HOCl) delivered a 300 times better kill rate than manual cleaning alone" Cunningham said. Additional results/features include "No microbial transfer, 64 percent improved labor efficiency; Microburst's concentrations are much lower than bleach or peroxide. Approximate 28-minute turnaround time of patient room after discharge with 100 percent surface contact. Immediate re-entry into room, no waiting. No line-of-sight issues are experienced, as with some other protocols. It is effective against C. difficile, MRSA, VRE, Staph, Pseudomonas, and others.
"Nimbus + Microburst reaches all areas of a hospital room, even under the bed and behind equipment. Nimbus + Microburst HOCl solution is different from ultraviolet - it is EPA registered - ultraviolet modalities are not. It is German-engineered, including a smart device with custom reporting capabilities, it delivers 100 percent room surface contact via Microburst solution atomization, delivering up to 99.999 percent kill rate of HAI-causing pathogen. Nimbus + Microburst delivers a repeatable, consistent, whole room disinfection process, eliminating user error has a short cycle time versus peroxide systems, with rapid dehumidification technology built into the system for immediate room re-entry."
Under the spotlight
Moving on to our ultraviolet and xenon disinfection suppliers, Xenex's Vice President of Sales and Account Management, Irene Hahn, takes Üre stage first. "Tire most important factor to consider when evaluating disinfection technologies is whether the technology and associated protocols have demonstrated a repeatable positive impact on reducing infection rates. Can tire vendor provide a list of multiple references from its client base drat can attest to infection rate reductions that provided a positive return on investment? IPs should also look at the peer reviewed, published outcome studies from hospitals who have deployed the technology. Were those reductions statistically significant?
"The LightStrike technology uses pulsed xenon to create intense, broad spectrum UV light. This broad spectrum light hits pathogens where they are the most vulnerable, so the LightStrike robots are able to quickly and efficiently kill microorganisms like C.diff, MRSA, CRE and VRE. A recently published study demonstrated the efficacy of the LightStrike technology at destroying an emerging pthorogen, Candida miris (Cauris). Several hospitals in Üre northeastern U.S. used threir LightStrike robots and Xenex's recommended protocols to disinfect rooms after treating Cauris patients. No new infections were reported.
Hospitals using LightStrike pulsed xenon UV disinfection technology usually report a quantifiable Return on Investment (ROI) as a result of fewer infections within a 6 to 9-month period. At Xenex, we've provided robots, customized protocols and training to a facility at no cost to prove that the technology is effective at helping them bring down infection rates. After a trial period, the hospital's infection rates had fallen dramatically and they not only decided to invest in the technology but deployed robots at their other facilities and continue to report success. Xenex has worked closely with hospitals to maximize operational efficiencies so room turnover time is minimal. Adding LightStrike disinfection robots to the patient room turnover process requires less than 7 minutes when leveraging our best practices and Under the spotlight recommended protocols. Xenex's LightStrike robots work very quickly because they emit UV light across the entire germicidal spectrum. It is the intensity of light and broad spectrum of UV produced that kills pathogens where they are most vulnerable. Tlris efficiency allows hospitals to disinfect exponentially more rooms per day (per robot) in order to truly bring down the bioburden within a facility."
Chuck Dunn, President and CEO of Tru-D discusses what his technology - powered by ultraviolet light - can do to reduce HAIs. "Our approach is to stay consistent with the current clinical literature," he said, pointing to the latest literature mentioned earlier by Dr. Rutala. "Tru-D ranks very high when healthcare purchasing leaders conduct proper due diligence. When considering one UVC product over another, hospitals must verify that company claims are evidence-based, they must confirm that a study cited is in fact specific to the product being offered, they must be certain studies are independent and not authored by company stakeholders, and it is critical to rely only on third-party research with no conflicts of interest that demonstrate the product's effectiveness in a real-world setting. The clinical literature is far from generic, and healthcare purchasing It executives must confirm product 1 capability claims are supported II with product-specific, independent scientific evidence.
"Tru-D is clinically supported by more than 20 independent, peer-reviewed, journal-published studies including the Benefits of Enhanced Terminal RoomDisinfection (BETR-Disinfection) randomized clinical trial that showed that Tru-D was able to reduce the relative risk of colonization and infection caused by epidemiologically important pathogens among patients admitted to the same room by a cumulative 30 percent in hospital settings with 93 percent compliance of standard disinfection protocols," Dunn continued. "Individual hospital results may vary. Tru-D is the only UVC disinfection device with patented Sensor360 technology that measures the precise dose needed for complete room disinfection. Tru-D7 s one placement positioning does not require the operator to move the device to multiple positions, leaving them free to complete other tasks during the disinfection cycle. Tru-D's Sensor360 technology that compensates for room variables, such as size, shape and contents in the room, ensures thorough disinfection for each unique space. This unique, patented feature reduces human error in device placement and cycle time selection delivering a consistent and documented baseline of disinfection for all targeted atrisk rooms. With Tru-D, cycle times vary to provide consistent disinfection in various size rooms. Patient rooms typically require 15 to 25 minutes. The Tru-D disinfection program training provides efficiencies that demonstrated when compared to average overall room turn times there was only the four-minute overall variance."
Larinda Becker, Healthcare Marketing, Diversey, said her company's product, the MoonBeam3, "is fast, effective, portable and affordable. With 3- minute cycles, the 39-pound unit can be effectively deployed by any staff member. Its articulating arms enable the user to optimize dose coverage on both horizontal and vertical surfaces. MoonBeam can be easily moved around the facility and requires minimal storage space. The product cycle for the MoonBeam3 is 3 minutes. We recommend dosing two sides of the room and the bathroom for each patient room. In general, the system can be "doubled" up to run simultaneous cycles in the patient room and a cycle in the bathroom while the staff member is finishing the room. It is estimated that a patient room can be done in as little as 12 minutes with a single unit (includes placement of the device and cycle times) or in as little 7 minutes with two units.
"Most importantly, it can be acquired and operated at a fraction of the cost of other units," Becker continued. "Operational leases (similar to renting), allow payments to be considered operational expenses, and allow the asset to stay off the balance sheet. In many cases, due to capital and time requirements, UV-C disinfection is being limited to a small sampling of rooms; however, with the recent launch of operational leases, requiring no capital expenditures and newer technologies that have faster cycle times and lower acquisition and use cost, UV-C can now be used more broadly across facilities. Increased deployment may also drive patient satisfaction by demonstrating a firm commitment to preventing infection. Programs are available for as little as $1000/month, and include the device, service and UV-C bulbs.
Gunner Lyslo, Founder and CEO, Surfacide, said his technology "addresses the role of shadows given our multiple emitter approach. Published data indicate that UV is a direct line of sight technology. When using three emitters during a single treatment cycle, most surfaces are within the direct line of sight and effectively treated. Single emitter systems should require frequent repositioning and extended run times. Surfacide's automated system provides shorter cycle times and increased staff productivity without repositioning.
"Distance is critical to UV-C efficacy; as the distance increases, less energy is delivered to surfaces," Lyslo continued. "Surfacide positions multiple emitters closer to surfaces, delivering more energy throughout the room in a single cycle. The paradigm shift in using UV Technology is it contemplates simple laws of physics vs. the chemistry of chemical based disinfectants. This is very easily explained through the Inverse Square Law that can be summarized in the following: as the distance from the emitting source is doubled, the energy is not reduced by 50 percent, it is reduced to 25 percent. The intensity of light is inversely proportional to the square of the distance."
Lyslo said most rooms can be treated within 15 minutes with the Surfacide technology. "ORs take slightly longer given they are larger," he said. "It is for this reason that these low five-minute disinfection cycles are simply not possible and defy the laws of physics. NO patient signs up for an infection while seeking care and patients expect to receive the highest level of care within the hospital. We believe that Surfacide collaborates with our healthcare customers to provide that."
Unlike the ultraviolet disinfection solutions discussed above, continuous, all-day LED versions that are safe for human exposure are also available.
"The biggest value-add that Vital Vio's proprietary antibacterial LED lighting technology brings (and what differentiates us from other hospital decontamination methods) is that our process is continuous versus intermittent," explained Kristin May, Chief Commercial Operations Officer at Vital Vio. "Other solutions on the market, such as ultraviolet light (UV), which is not safe for human exposure, is only able to provide what is known as a "terminal" clean, which sanitizes spaces once patients and staff are no longer using the room. In between these cleanings, bacteria can easily form and spread, leaving patients, doctors and visitors at risk until the next wave of disinfection. While UV light is extremely powerful, it's also especially dangerous to humans, directly impacting the DNA in people, animals and plants, along with bacterial cells.
"Alternatively, by adopting a continuous disinfection approach, health systems can protect against HAIs in a way that isn't potentially harmful to patients and doctors. In Vital Vio's case, we insert bacteria-killing, visible LED lighting that can be used 24/7/365 - both with overhead lighting in large environments, and within smaller spaces like consumer appliances," May continued. "This creates a multi-layered germ defense system that not only disinfects, but maintains disinfection, preventing the regeneration and spread of germs." HPN